

**Sunday, 15. June 2025***Pre-Congress Course*

09:00 - 15:00

PCR1

**CINP Research Fellowships 2025 Colloquium (By Invitation Only)***Chair:* Matthew Kang (Melbourne, Australia)*Chair:* Shyh-Yuh Wei (Tainan, Taiwan)**Get Together**

09:00 - 09:15

**Welcome and Introductions**

09:15 - 09:30

*Speaker:* Matthew Kang (Melbourne, Australia)*Speaker:* Shyh-Yuh Wei (Tainan, Taiwan)**Multiple facets of research in Alcohol Use Disorder (AUD)**

09:30 - 10:10

*Speaker:* Ming-Chyi Huang (Taipei, Taiwan)**Importance of Preclinical Research & Yes of BioCommons/Data Science to Link Preclinical and Clinical Research**

10:10 - 10:40

*Speaker:* Rachel Hill (Clayton, Australia)**Discussion & Coffee Break**

10:40 - 11:10

**Fellowship Project Plan Discussion and Refinement**

11:10 - 12:30

*Speaker:* Ming-Chyi Huang (Taipei, Taiwan)*Speaker:* Rachel Hill (Clayton, Australia)*Speaker:* Matthew Kang (Melbourne, Australia)*Speaker:* Shyh-Yuh Wei (Tainan, Taiwan)**Discussion & Lunch**

12:30 - 13:30

*Session*

14:00 - 15:00

PCR2

**Innovative Perspectives in Neuropsychopharmacology: Insights from Indonesia and Australia***Chair:* Yuki Moriya (Tokyo, Japan)**Effect of Fluoxetine to Progressivity of Intervertebral Disc Disorder of Patients with Psychiatric Comorbidity in Maria Walanda Maramis District General Hospital of North Minahasa, Indonesia**

14:00 - 14:15

*Speaker:* Ireine Suantika Cornelia Roosdy (Manado, Indonesia)**Innovative perspectives in neuropsychopharmacology: insights from Indonesia, NewZealand and Australia**

14:15 - 14:30

*Speaker:* Suzy Yusna Dewi (Jakarta, Indonesia)**Comparison of features of relapse risk between alcohol-dependent individuals in Japan and Australia through use of validated self-rating scale: the Alcohol Relapse Risk Scale**

14:30 - 14:45

*Speaker:* Shijia Winson Lu (Sydney, Australia)**Experiences with Nitazene Withdrawal**

14:45 - 15:00

*Session*

15:15 - 16:30

PCR2

**Cutting-Edge Clinical and Basic Research on Mental Disorders: Perspectives from Indonesian Psychiatry Experts***Chair:* Andi Tanra (Makassar, Indonesia)**Adoption of Japanese Spiritual and Religious Approaches for Disaster Recovery and Awareness in Indonesia**

15:15 - 15:30

*Speaker:* Era Catur Prasetya (East Java, Indonesia)**Unmet needs of abandoned older adults with mental disorders in Institutional Care**

Speaker: Arundhati Nugrahaning Aji (Jakarta, Indonesia)	15:30 - 15:45
<b>The Role of SSRIs in Improving Cognitive Impairment in an Adolescent with Trauma: A Case Study in Indonesia</b>	15:45 - 16:00
Speaker: Frilya Rachma Putri (Malang East Java, Indonesia)	
<b>Alpha Brain Wave Stimulation in Reducing Depression in Chronic Pain</b>	16:00 - 16:15
Speaker: Santi Yuliani (Magelang, Indonesia)	
<b>Community Health Empowerment for Early-Detecting and Reintegrating of Schizophrenia in Indonesia</b>	16:15 - 16:30
Speaker: Citra Fitri Agustina (Jakarta Pusat, Indonesia)	
Networking 15:45 - 16:45	SR
<b>Early Career Welcome Reception</b>	
Plenary 17:00 - 18:00	PL
<b>Opening &amp; Awards Ceremony</b>	
Plenary 18:00 - 19:00	PL
<b>Plenary 1: Keynote Lecture Guy Goodwin</b>	
Chair: Hiroyuki Uchida (Japan)	
Chair: Tung-Ping Su (Taipei, Taiwan)	
<b>Can We Re-Medicalise the Psychedelic Experience?</b>	18:00 - 19:00
Speaker: Guy Goodwin (Oxford, United Kingdom)	
Networking 18:30 - 20:00	SR
<b>OPEN: Exhibition &amp; CINP Members' Lounge</b>	
Networking 19:00 - 20:00	SR
<b>Welcome Reception</b>	

## Monday, 16. June 2025

### Plenary

09:10 - 10:10

PL

#### Plenary 2: Keynote Lecture Sarah Medland

Chair: Lucie Bartova (Vienna, Austria)

Chair: Miho Terunuma (Japan)

#### Plenary Lecture 2: What have we learned from 15 years of collaborative neuroimaging research in the ENIGMA consortium

09:10 - 10:10

Speaker: Sarah Medland (Brisbane, Australia)

### Networking

09:30 - 17:00

SR

#### OPEN: Exhibition & CINP Members' Lounge

### Break

10:10 - 10:50

SR

#### Morning Coffee Break

### Posters

10:15 - 10:45

EXH

#### Poster Session 1: Schizophrenia

Chair: Noboru Hiroi (San Antonio, United States)

#### Therapeutic potential of brain-penetrating nanoparticles containing a selective VIP receptor 2 (VIPR2) antagonist peptide for schizophrenia

10:15 - 10:15

Speaker: Yukio Ago (Hiroshima, Japan)

#### Maternal immune activation leads to schizophrenia-related behavioural and neurophysiological deficits in mothers and juvenile offspring

10:15 - 10:15

Speaker: Francis Bambico (St. John's, Canada)

#### Effects of prenatal cannabinoids exposure: assessing the role of the endocannabinoid system in a neurodevelopmental animal model of psychopathology

10:15 - 10:15

Speaker: Vincenzo Micalé (Catania, Italy)

#### Effect of GAD67 deletion in the thalamic reticular nucleus on sensory gating and sleep spindle activity

10:15 - 10:15

Speaker: Hideki Miwa (Tokyo, Japan)

#### Effect of developmental deficits in ventral hippocampal excitatory and inhibitory neurons in schizophrenia-relevant phenotypes in mice

10:15 - 10:15

Speaker: Lalit K. Srivastava (Montreal, Canada)

#### In vivo effects and molecular mechanism of a nanozyme-based artificial peroxisome on alleviating schizophrenia

10:15 - 10:15

Speaker: Bo Pan (Yangzhou, China)

#### Effects of antipsychotics and prenatal Poly I:C exposure on GSK3 $\beta$ -mediated signaling and NMDA/GABA receptors in the dorsal raphe nucleus of rats

10:15 - 10:15

Speaker: Shiyen Chen (Fuzhou, China)

#### Comparison of Brain age deviations among patients with schizophrenia, bipolar disorder, and major depressive disorder

10:15 - 10:15

Speaker: Ya Mei Bai (Taipei, Taiwan)

<b>Neuromelanin Accumulation and Treatment Responsiveness in Patients with Schizophrenia: A Cross-Sectional Study with Neuromelanin-Sensitive MRI</b>	10:15 - 10:15
<i>Speaker:</i> Fumihiko Ueno (Toronto, Canada)	
<b>Genetic evidence for the association between schizophrenia and obesity</b>	10:15 - 10:15
<i>Speaker:</i> Shi-Heng Wang (Zhunan, Taiwan)	
<b>Validity of a smartphone application for self-monitoring psychiatric symptoms in patients with schizophrenia</b>	10:15 - 10:15
<i>Speaker:</i> Cheol Park (Gwang-Ju, Korea, Republic of)	
<b>Temporal Dynamics of Gut Fungi in Drug-Naïve First-Episode Schizophrenia Patients During Antipsychotics Treatment</b>	10:15 - 10:15
<i>Speaker:</i> Xue Zhao (Shanghai, China)	
<b>Using minor physical anomalies to predict treatment resistance in schizophrenia patients through machine learning</b>	10:15 - 10:15
<i>Speaker:</i> Chih-Wei Lin (Tainan, Taiwan)	
<b>Distinct and Common Subcortical Functional Connectivity Revealed Across Three Major Psychiatric Disorders</b>	10:15 - 10:15
<i>Speaker:</i> Duan-Pei Hung (Taipei, Taiwan)	
<b>Incidence of psychosis and its risk factors and mortality in North Korean Defectors compared to South Korean controls</b>	10:15 - 10:15
<i>Speaker:</i> Thi-Hung Le (Jeonju, Korea, Republic of)	
<b>Screening of schizophrenia biomarkers based on proteomics and their application in early diagnosis</b>	10:15 - 10:15
<i>Speaker:</i> Fang Dong (Beijing, China)	
<b>Impairment of the enhancement effect of perceived spatial separation on prepulse inhibition of Startle in first-episode Schizophrenia and clinical high risk for psychosis</b>	10:15 - 10:15
<i>Speaker:</i> Yue Sun (Beijing, China)	
<b>Altered auditory network functional connectivity in psychotic disorder not other specified</b>	10:15 - 10:15
<i>Speaker:</i> Woo-Sung Kim (Jeon-ju, Korea, Republic of)	
<b>Antipsychotic Medications and Risk Profiles Associated with Pneumonia in Patients with Schizophrenia Receiving Home-Care Case Management Intervention in Taiwan</b>	10:15 - 10:15
<i>Speaker:</i> Chian-Jue Kuo (Taipei, Taiwan)	
<b>Saliva versus Plasma Therapeutic Drug Monitoring of Clozapine and Norclozapine</b>	10:15 - 10:15
<i>Speaker:</i> Jimmy Lee (Singapore, Singapore)	
<b>Associations of polygenic risk scores differentiating attention-deficit hyperactivity disorder from autism spectrum disorder with cognitive and cortical alterations in schizophrenia patients</b>	10:15 - 10:15
<i>Speaker:</i> Ayumi Kuramitsu (Gifu, Japan)	
<b>Structural brain differences in individuals at clinical high risk for psychosis</b>	10:15 - 10:15
<i>Speaker:</i> Yimeng Wang (Beijing, China)	
<b>Leveraging white matter microstructural features to construct a high-performance diagnostic classifier for clinical high-risk for psychosis</b>	10:15 - 10:15
<i>Speaker:</i> Zhenzhu Chen (Beijing, China)	
<b>Differences in the effects of antipsychotic drug-induced</b>	10:15 - 10:15

<b>hyperprolactinemia in adolescent and adult schizophrenia patients: a retrospective pilot study</b>		
<i>Speaker:</i> Lei Zhang (Shanghai, China)		
<b>The effect of bright light therapy on symptoms and cognitive function in patients with schizophrenia</b>	10:15 - 10:15	
<i>Speaker:</i> Ran Wang (Shijiazhuang, China)		
<b>Problematic gambling and psychotic-like experiences: Findings from Japan</b>	10:15 - 10:15	
<b>Medicinal cannabis an mental health hospitalisation: an observational study</b>	10:15 - 10:15	
<i>Speaker:</i> Fehim Puris (Brisbane, Australia)		
<b>Relationship between clozapine:norclozapine ratio and cognitive function and employment status in treatment resistant schizophrenia</b>	10:15 - 10:15	
<i>Speaker:</i> Jiaqian Sun (Singapore, Singapore)		
<b>The effect of sodium benzoate treatment for treatment resistant schizophrenia and its association with glutamate concentration: a pilot study with proton magnetic resonance spectroscopy</b>	10:15 - 10:15	
<i>Speaker:</i> Yen Kuang Yang (Tainan, Taiwan)		
<b>The association between cognitive inflexibility and decline deviation from fNIRS-measured brain function in schizophrenia</b>	10:15 - 10:15	
<i>Speaker:</i> Han-Yu Chuang (Taichung, Taiwan)		
<b>Distinct signatures of OSSOs compared to SSDs and HC using graph theory analysis</b>	10:15 - 10:15	
<i>Speaker:</i> Soyolsaikhan Odkhuu (Jeonju, Korea, Republic of)		
<b>Effectiveness of long-acting injectable paliperidone palmitate on relapse prevention of schizophrenia</b>	10:15 - 10:15	
<i>Speaker:</i> Yung-Chieh Yen (Kaohsiung, Taiwan)		
<b>Retrospective study for correlation with reducing antiparkinsonian anticholinergic drugs and adverse effects</b>	10:15 - 10:15	
<i>Speaker:</i> Hirotaka Sekiguchi (Toyoake, Japan)		
<b>In vivo assessments of tau pathologies in patients with late-onset psychosis: a PET study</b>	10:15 - 10:15	
<i>Speaker:</i> Manabu Kubota (Chiba, Japan)		
<b>Obesity associated with symptomatic remission in clozapine-treated individuals with treatment resistant schizophrenia</b>	10:15 - 10:15	
<i>Speaker:</i> Daniel Chang (Singapore, Singapore)		
<b>A case of cryptococcal meningitis &amp; Anti-NMDAR encephalitis in a patient with myelofibrosis in rural Victoria</b>	10:15 - 10:15	
<i>Speaker:</i> Benjamin Neale (Traralgon, Australia)		
<i>Symposium</i>		
10:50 - 12:05		PL
<b>Symposium 1: 5HT7 and 5HT4 Receptor Systems as Therapeutic Targets in Mood Disorders: What is New?</b>		
<i>Chair:</i> Lakshmi Yatham (Vancouver, Canada)		
<b>Evaluating the Promise of the 5HT7 Receptor as a Therapeutic Target in Mood Disorders: A Review and New Neuroimaging Data</b>	10:50 - 11:15	
<i>Speaker:</i> Paul Stokes (London, United Kingdom)		
<b>A randomized double blind placebo controlled trial of lurasidone in improving cognitive impairment in euthymic patients with bipolar</b>	11:15 - 11:40	

**disorder**

Speaker: Lakshmi N. Yatham (Vancouver, Canada)

**Effect of Antidepressant Treatment on 5-HT<sub>4</sub> Receptor Binding and Associations With Clinical Outcomes and Verbal Memory in Major Depressive Disorder** 11:40 - 12:05

Speaker: Vibe Frokjae (Copenhagen, Denmark)

**Symposium**

10:50 - 12:05

S1

**Symposium 2: Moving Backward: From Treatment to Prevention in PTSD, Harnessing Neuroscience, Psychology, and Digital Tools**

Chair: Joseph Zohar (Ramat Gan, Israel)

**Scaling Digital Therapeutics for Post-Disaster Scenarios Using Generative Artificial Intelligence** 10:50 - 11:15

Speaker: Rahul Khanna (Melbourne, Australia)

**Enhancing resilience in leveraging digital therapeutics, AI, as Golden hour opportunities for personalized interventions in prevention and treatment of PTSD** 11:15 - 11:40

Speaker: Eric Vermetten (Leiden, Netherlands)

**A randomised controlled trial of a smartphone application as an early intervention to reduce symptoms of depression, anxiety and posttraumatic stress in first responders** 11:40 - 12:05

Speaker: Meaghan O'Donnell (Melbourne, Australia)

**Symposium**

10:50 - 12:05

S2

**Symposium 3: Update on the Clinical Utility of PsychoPharmacogenetics**

Chair: Allan Young (London, United Kingdom)

**Pharmacogenetic-supported prescribing for kids with mental health conditions** 10:50 - 11:15

Speaker: Chad Bousman (Calgary, Canada)

**A large RCT on a combinatorial pharmacokinetic pathway PGx** 11:15 - 11:40

Speaker: Malcolm Hopwood (Melbourne, Australia)

**An overview of the project exploring gene-drug pairs in dose guidance of antidepressants and antipsychotics** 11:40 - 12:05

Speaker: Roos van Westrhenen (Amsterdam, Netherlands)

**Session**

10:50 - 12:05

S3

**AsCNP Award Lecture**

Chair: Suresh Sundram (Clayton, Australia)

Chair: Shih-Ku Lin (Taipei, Taiwan)

**Exploring Asian Neuropsychopharmacological Research: Polypharmacy, Microglia, and Hikikomori Beyond Western Perspectives** 10:50 - 11:25

Speaker: Takahiro A. Kato (Hokkaido, Japan)

**Decoding Neuroimmune Mechanisms in Stress-Related Neuropsychiatric Disorders** 11:25 - 12:00

Speaker: Tomoyuki Furuyashiki (Kobe, Japan)

**Q&A, Discussion** 12:00 - 12:05

*Data Blitz Session*

10:50 - 12:05

M1

**Data Blitz 1: Addiction related**

Chair: Pin-Yen Lu (Kaohsiung, Taiwan)

**Targeting opioid neurotransmission in borderline personality disorder with self-harming behavior: Preliminary findings of a [<sup>11</sup>C]NOP-1A positron emission tomography study**

10:50 - 10:56

Speaker: Nathan Kolla (Saskatoon, Canada)

**An electroencephalography connectome predictive model of craving for methamphetamine**

10:56 - 11:02

Speaker: Di Zhao (Shanghai, China)

**Repetitive Transcranial Magnetic Stimulation (rTMS) in the management of alcohol dependence and other substance abuse disorders - emerging data and clinical relevance**

11:02 - 11:08

Speaker: Venu Gopal Jhanwar (Varanasi, India)

**Adolescent THC Exposure Enhances Impulsivity in Adulthood: Insights from a WIN 55,212-2 Self-Administration Mouse Model**

11:08 - 11:14

Speaker: Elena Martín García (Barcelona, Spain)

**Disruption of kinematic phenotypes induced by cannabinoid agonist and harmaline in marker-based 3D motion capture of freely moving mice**

11:14 - 11:20

Speaker: Bogna Ignatowska-Jankowska (Onna, Japan)

**Medication-seeking behaviors and correlated characteristics of Zolpidem users in Taiwan - a shared patient network analysis**

11:20 - 11:26

Speaker: Wei-Chen Lee (New Taipei City, Taiwan)

**Symptom based pharmacotherapy of borderline personality disorder**

11:26 - 11:32

Speaker: Rajesh Nagpal (New Delhi, India)

**Discussion, Q&A**

11:32 - 12:05

*Meet the Experts / Campfire Session*

10:50 - 11:50

M2

**Campfire Session:**

**The Good, the Bad, and the Rejected: Tales from Editors (LIMITED SEATS)**

Chair: Gregers Wegener (Aarhus, Denmark)

**The Good, the Bad, and the Rejected: Tales from Editors**

10:50 - 11:50

Speaker: Gregers Wegener (Aarhus, Denmark)

Speaker: Anthony Grace (Pittsburgh, United States)

*Spotlight Session*

12:15 - 13:15

PL

**Spotlight Session 1: Neuropsychopharmacology of Seizure and Psychotic Disorders**

Chair: Johnny Lokin (Philippines)

**Overlapping Pathophysiology of Seizures and Psychosis**

12:15 - 12:35

Speaker: Marc Fernandez (Philippines)

**The Role of Neuroinflammation in the Intersection of Epilepsy and Psychosis**

12:35 - 12:55

Speaker: Gerardo Salazar (Philippines)

**Novel Therapeutic Targets in Epilepsy-Psychosis Spectrum Disorders**

12:55 - 13:15

Speaker: Alejandro Baroque II (Philippines)

*Data Blitz Session*

12:15 - 13:15

S1

**Data Blitz 2: Depression characterization**

*Chair:* Diego A. Pizzagalli (Belmont, United States)

**Risk factors and psychotropic medication influence in the progression from major depression to bipolar disorder: findings from a 16-year study**

12:15 - 12:21

*Speaker:* Ying-Ting Chao (Taipei, Taiwan)

**Plasma Neurofilament Light and Glial Fibrillary Acidic Protein are Elevated in Bipolar Disorder: Evidence for Neuroprogression and Astrogliosis**

12:21 - 12:27

*Speaker:* Matthew Kang (Melbourne, Australia)

**The neuroanatomy of postpartum depression: Insights from a cross-sectional structural MRI study**

12:27 - 12:33

*Speaker:* Sofia Attolini (Berlin, Germany)

**Correlation of Mood Symptoms and the Seasonal Variation of Vitamin D Levels in Taiwanese Mood Disorder Patients and Healthy Individuals: A Comparative Cohort Study**

12:33 - 12:39

*Speaker:* Chun-I Liu (Taipei, Taiwan)

**Integration analysis of gut microbiome and serum proteome in patients with unipolar and bipolar depressive episodes**

12:39 - 12:45

*Speaker:* Cuixia An (Shijiazhuang, China)

**Fibroblast growth factor 2 modulates central monoaminergic neurons *in vivo***

12:45 - 12:51

*Speaker:* Ruslan Paliokha (Bratislava, Slovakia)

**Small molecule-driven Arginase-1<sup>+</sup> microglial phenotype suppresses chronic stress-induced microglial engulfment and neuroinflammation via a PPAR $\gamma$ -dependent mechanism**

12:51 - 12:57

*Speaker:* Naijun Yuan (Guangzhou, China)

**Assessment of resting state functional Magnetic Resonance Imaging (fMRI) connectivity among patients with major depressive disorder**

12:57 - 13:03

*Speaker:* Paramdeep Singh (Bathinda, India)

**Evaluating apelin as a potential biomarker in major depressive disorder: correlation with clinical symptomatology**

13:03 - 13:09

*Speaker:* Enkhmurun Chibaatar (Kitakyushu, Japan)

**Progress of transcriptomic and epigenomes study in the depression and suicide study**

13:09 - 13:15

*Speaker:* Qingzhong Wang (Birmingham, United States)

*Data Blitz Session*

12:15 - 13:15

S2

**Data Blitz 3: Mood, clinical-related**

*Chair:* Ya Mei Bai (Taipei, Taiwan)

**The effects of ebselen addition on Glx and glutamate levels in the anterior cingulate cortex in clinically depressed patients taking antidepressant medication**

12:15 - 12:21

*Speaker:* Fitri Fareez Ramli (Oxford, United Kingdom)

**Adherence and engagement metrics with the novel prescription digital therapeutic, CT-152**

12:21 - 12:27

*Speaker:* Tarolyn Carlton (Princeton, United States)

**Comparative analysis of gut microbiota and functional pathways in**

12:27 - 12:33



<b>antidepressant-treated vs. antidepressant-naïve depression patients and healthy controls</b>		
<i>Speaker:</i> Shih Kai Lin (Taipei, Taiwan)		
<b>Early antibiotic exposure and risk of psychiatric and neurocognitive outcomes: results of a systematic review and meta-analysis</b>	12:33 - 12:39	
<i>Speaker:</i> Jessica Green (Geelong, Australia)		
<b>Targeting Ruminative Thinking Through Brain Training</b>	12:39 - 12:45	
<i>Speaker:</i> Katie Douglas (Christchurch, New Zealand)		
<b>Emotional faces memory task performance and clinical outcomes for the novel prescription digital therapeutic, CT-152</b>	12:45 - 12:51	
<i>Speaker:</i> Jeffrey Cochran (Princeton, United States)		
<b>Assessing and managing cigarette smoking among psychiatric inpatients: clinical and sociodemographic implications</b>	12:51 - 12:57	
<i>Speaker:</i> Maurizio Pompili (Rome, Italy)		
<b>The adverse experiences, social support, and neurochemical alterations in bipolar disorder: a focus on history of psychotic features</b>	12:57 - 13:03	
<i>Speaker:</i> Sriyani Padmalatha Konara Mudiyansele (Tainan, Taiwan)		
<b>Investigating the hemodynamic response to iTBS of the left DLPFC: a concurrent iTBS/fNIRS study</b>	13:03 - 13:09	
<i>Speaker:</i> Weili Xia (Hong Kong, China)		
<b>Mitochondrial DNA copy number as a mediator of the relationship between insulin resistance and cognitive function in patients with euthymic bipolar disorder</b>	13:09 - 13:15	
<i>Speaker:</i> Tsung-Han Tsai (Tainan, Taiwan)		
<i>Featured Communication</i>		
12:15 - 13:15		S3
<b>Featured Communication 1: Depression clinical</b>		
<i>Chair:</i> Yen Kuang Yang (Tainan, Taiwan)		
<b>Efficacy of Silexan in Patients with a Major Depressive Episode - Results from a Multi-centre, Double-blind, Randomised, Placebo- and Reference-controlled Phase III Trial</b>	12:15 - 12:30	
<i>Speaker:</i> Siegfried Kasper (Vienna, Austria)		
<b>Changes in Quality of Life and Productivity Gain among Esketamine Responders in a Real-world Study in Australia and New Zealand</b>	12:30 - 12:45	
<i>Speaker:</i> Malcolm Hopwood (Melbourne, Australia)		
<b>Polygenic risk analyses of venlafaxine-related side effects in older adults with depression</b>	12:45 - 13:00	
<i>Speaker:</i> Daniel Mueller (Toronto, Canada)		
<b>Discussion, Q&amp;A</b>	13:00 - 13:15	
<i>Selected Colloquium</i>		
12:15 - 13:15		M1
<b>Selected Colloquium 6: Precision Psychiatry CINP GNC symposium: From biomarker discovery to therapeutic innovation toward personalized mental health care</b>		
<i>Chair:</i> Bernhard Baune (Münster, Germany)		
<b>Precision psychiatry: contributions from brain imaging, genetics, iPSC</b>	12:15 - 12:35	
<i>Speaker:</i> Dan Rujescu (Wien, Austria)		
<b>Decoding the biomolecular landscape of psychiatric disorders for</b>	12:35 - 12:55	

<b>improving patient stratification</b>		
<i>Speaker:</i> Stefano Comai (Padova, Italy)		
<b>Translational implications of ongoing protocols in Precision Psychiatry</b>	12:55 - 13:15	
<i>Speaker:</i> Bernhard Baune (Münster, Germany)		
<i>Meet the Experts / Campfire Session</i>		
12:15 - 13:15		M2
<b>Meet the Expert 1: OCD (LIMITED SEATS)</b>		
<i>Chair:</i> Joseph Zohar (Ramat Gan, Israel)		
<b>OCD: Case Discussions</b>	12:15 - 13:15	
<i>Speaker:</i> Joseph Zohar (Ramat Gan, Israel)		
<i>Speaker:</i> Zhen Wang (China)		
<i>Speaker:</i> Vlasios Brakoulas (Australia)		
<i>Break</i>		
13:15 - 14:40		SR
<b>Lunch Break</b>		
<i>Sponsored Symposium</i>		
13:25 - 14:25		S2
<b>Sponsored Lunch Symposium</b>		
<i>Sponsored Symposium</i>		
13:25 - 14:25		S3
<b>Sponsored Lunch Symposium</b>		
<i>Symposium</i>		
14:40 - 15:55		PL
<b>Symposium 4: Psychedelics: From Bench to Clinic</b>		
<i>Chair:</i> Bernard Lerer (Jerusalem, Israel)		
<b>Distinct Behavioral and Pharmacological Effects of Psilocybin and Lisuride</b>	14:40 - 15:05	
<i>Speaker:</i> Gabriella Gobbi (Montreal, Canada)		
<b>Psychedelics and OCD: translational approaches</b>	15:05 - 15:30	
<i>Speaker:</i> Bernard Lerer (Jerusalem, Israel)		
<b>Clinical evidence and applications of psychedelics for mental illnesses</b>	15:30 - 15:55	
<i>Speaker:</i> Hideaki Tani (Tokyo, Japan)		
<i>Symposium</i>		
14:40 - 15:55		S1
<b>Symposium 5: New roles for neuromodulation in cognitive function and related disorders</b>		
<i>Chair:</i> Satoshi Kida (Tokyo, Japan)		
<b>Memory modulation by dopamine-cAMP signal transduction pathways</b>	14:40 - 15:05	
<i>Speaker:</i> Satoshi Kida (Tokyo, Japan)		
<b>A modulatory brain circuit involved in the cognitive control of choice and decision-making and its disorders</b>	15:05 - 15:30	
<i>Speaker:</i> Bernard Balleine (Sydney, Australia)		
<b>Neuromodulation of amygdala-mediated affective learning</b>	15:30 - 15:55	

Speaker: Andrew Holmes (Bethesda, United States)

## Symposium

14:40 - 15:55

S2

### Symposium 6: Pre- and postnatal maternal health and child outcomes

Chair: Cristiana Cruceanu (Stockholm, Sweden)

**The long-term effects of reproductive experience on anxiety and its pharmacological treatment: a cross-species approach in rats and humans**

14:40 - 15:05

Speaker: Jodie Pestana (Sydney, Australia)

**Prenatal stress exposure shapes corticogenesis through cell fate and gene regulatory networks with implications for neurodevelopmental disorders**

15:05 - 15:30

Speaker: Cristiana Cruceanu (Stockholm, Sweden)

**Delineating the impact of early life adversity on the cellular and molecular architecture of the human brain.**

15:30 - 15:55

Speaker: Natalie Matosin (Sydney, Australia)

## Spotlight Session

14:40 - 15:40

S3

### Spotlight Session 2: NextGen Taiwan Researchers Forum

Chair: Po-See Chen (Taiwan)

**The effect of combined theta burst stimulation on functional connectivity of the thalamus and putamen in patients with gambling disorder**

14:40 - 14:46

Speaker: Shu-Wei Liu (Taipei, Taiwan)

**Distinct and Common Subcortical Functional Connectivity Revealed Across Three Major Psychiatric Disorders**

14:46 - 14:52

Speaker: Duan-Pei Hung (Taipei, Taiwan)

**Distinctive association patterns between topological properties of brain structural networks and social cognition in euthymic bipolar disorder**

14:52 - 14:58

Speaker: Tsai Chung Hahn (Tainan, Taiwan)

**Predicting rTMS treatment response in depression: use of machine learning models to identify the roles of metabolic and clinical factors**

14:58 - 15:04

Speaker: I Chun Liu (Tainan City, Taiwan)

**Using Classification and Regression Tree Modelling to Investigate Low-Dose Ketamine's Effect on Remission of Suicidal Symptoms Among Patients with Treatment-Resistant Depression and Strong Suicidal Thought**

15:04 - 15:10

Speaker: Ping Chung Wu (Taipei, Taiwan)

**Mitochondrial DNA copy number as a mediator of the relationship between insulin resistance and cognitive function in patients with euthymic bipolar disorder**

15:10 - 15:16

Speaker: Tsung-Han Tsai (Tainan, Taiwan)

**Abnormalities of Subcortical Brain Volume throughout the Psychosis Course**

15:16 - 15:22

Speaker: Yi-An Liao (Taipei, Taiwan)

**Age-specific variations in antidepressant efficacy of transcranial magnetic stimulation for treatment-resistant depression: a real-world retrospective study**

15:22 - 15:28

Speaker: Jia Shyun Jeng (Taipei, Taiwan)

<b>OPRM1 A118G Polymorphisms and Naltrexone Treatment Response among Taiwanese Patients with Alcohol Use Disorder</b>	15:28 - 15:34
<i>Speaker:</i> Yan-Jiun Hung (Taipei, Taiwan)	
<b>Cannabidiol mitigates cognitive deficits in a mouse model of Alzheimer's disease</b>	15:34 - 15:40
<i>Speaker:</i> Yi-Chia Chen (Tainan, Taiwan)	
<i>Featured Communication</i>	
14:40 - 15:55	M1
<b>Featured Communication 2: Different clinical disorders</b>	
<i>Chair:</i> Christopher Davey (Melbourne, Australia)	
<b>The efficacy of deep brain stimulation of combined anterior limb of internal capsule and nucleus accumbens for treatment-refractory obsessive-compulsive disorder: a randomised, double-blinded, and sham-controlled study</b>	14:40 - 14:55
<i>Speaker:</i> Jiayue Cheng (Shanghai, China)	
<b>Comprehensive gene expression analysis of GABAergic neurons-derived from iPS cells of patients with fibromyalgia accompanied by psychiatric symptoms</b>	14:55 - 15:10
<i>Speaker:</i> Naoko Kuzumaki (Tokyo, Japan)	
<b>Moderated Discussion, Q&amp;A</b>	15:10 - 15:40
<i>Meet the Experts / Campfire Session</i>	
14:40 - 15:40	M2
<b>Meet the Expert 2: PTSD (LIMITED SEATS)</b>	
<i>Chair:</i> Eric Vermetten (Leiden, Netherlands)	
<b>PTSD: Case Discussions</b>	14:40 - 15:40
<i>Speaker:</i> Eric Vermetten (Leiden, Netherlands)	
<i>Speaker:</i> Meaghan O'Donnel (Melbourne, Australia)	
<i>Speaker:</i> Rahul Khanna (Melbourne, Australia)	
<i>Posters</i>	
15:55 - 16:35	EXH
<b>Poster Session 2: Addiction Disorders, Sleep Disorders, Variable</b>	
<i>Chair:</i> Zhen Wang (China)	
<b>Sex-Specific Effects of Repeated Ketamine Exposure on Locomotor Activity in Mice: Influence of Social and Isolated Housing Conditions</b>	15:55 - 15:55
<i>Speaker:</i> Yuki Moriya (Tokyo, Japan)	
<b>Dynamic rewiring of neural circuits in the prelimbic cortex in meth abstinence</b>	15:55 - 15:55
<i>Speaker:</i> Sai Shi (Shanghai, China)	
<b>Oxytocinergic input from the paraventricular nucleus to the nucleus accumbens core modulates methamphetamine-conditioned place preference</b>	15:55 - 15:55
<i>Speaker:</i> Manqing Wu (Shanghai, China)	
<b>Psilocybin does not induce conditioned place preference, but modifies behavioral patterns in Sprague-Dawley rats</b>	15:55 - 15:55
<i>Speaker:</i> Gabriella Gobbi (Montreal, Canada)	
<b>The Bidirectional Claustrum-Anterior Cingulate Cortex Circuit Differentially Regulates Methamphetamine Taking and Seeking in a Rodent Self-Administration Model</b>	15:55 - 15:55
<i>Speaker:</i> Manqing Wu (Shanghai, China)	

<b>N-Acetylcysteine Mitigates Reinstatement of Ketamine Seeking in Rats</b>	15:55 - 15:55
<b>Salience network alterations related to personality traits in adolescents with excessive smartphone use</b>	15:55 - 15:55
<i>Speaker:</i> Min Kyung Hu (Seoul, Korea, Republic of)	
<b>Shared genetic architectures between methamphetamine use and other psychiatric disorders</b>	15:55 - 15:55
<i>Speaker:</i> Yen-Feng Lin (Zhunan Town, Miaoli County, Taiwan)	
<b>OPRM1 A118G Polymorphisms and Naltrexone Treatment Response among Taiwanese Patients with Alcohol Use Disorder</b>	15:55 - 15:55
<i>Speaker:</i> Yan-Jiun Hung (Taipei, Taiwan)	
<b>The effect of combined theta burst stimulation on functional connectivity of the thalamus and putamen in patients with gambling disorder</b>	15:55 - 15:55
<i>Speaker:</i> Shu-Wei Liu (Taipei, Taiwan)	
<b>Comparison of features of relapse risk between alcohol-dependent individuals in Japan and Australia through use of validated self-rating scale: the Alcohol Relapse Risk Scale</b>	15:55 - 15:55
<i>Speaker:</i> Shijia Winson Lu (Sydney, Australia)	
<b>Association between venlafaxine use and the risk of substance withdrawal in patients with nonopioid substance use</b>	15:55 - 15:55
<i>Speaker:</i> Shyh-Yuh Wei (Tainan, Taiwan)	
<b>The effects of yoga therapy on stigma in patients with alcohol use disorders: A single-blind randomized controlled study (Preliminary report)</b>	15:55 - 15:55
<i>Speaker:</i> Saeko Ikai-Tani (Tokyo, Japan)	
<b>HTR2A expression levels are correlated with the release of neurofilament light chain</b>	15:55 - 15:55
<i>Speaker:</i> Hsiang-Wei Kuo (Miaoli County, Taiwan)	
<b>Clinical value of predicting relapse within 3 months in patients with alcohol dependence based on functional near-infrared spectroscopy during a verbal fluency task</b>	15:55 - 15:55
<i>Speaker:</i> Lan Wang (Shijiazhuang, China)	
<b>Game motivation affects whether players benefit or suffer from games</b>	15:55 - 15:55
<i>Speaker:</i> Yuchen Huang (Beijing, China)	
<b>Is immunological gluten sensitivity a risk factor of development of eating disorder with low body weight?</b>	15:55 - 15:55
<i>Speaker:</i> Hisashi Yamada (Nishinomiya, Japan)	
<b>The relationship between sleep quality and neurocognitive function in the geriatric depression: a case-control study</b>	15:55 - 15:55
<i>Speaker:</i> Yu-Shu Huang (Taoyuan, Taiwan)	
<b>Ramelteon reduced anxiety/depression and sleep problems among shift workers</b>	15:55 - 15:55
<i>Speaker:</i> Chin-Bin Yeh (Taipei, Taiwan)	
<b>The population based risk of obstructive sleep apnea and psychiatric disorder</b>	15:55 - 15:55
<i>Speaker:</i> Chuan-Yi Kao (Taichung, Taiwan)	
<b>Sex differences in the amygdala and bed nucleus of the stria terminalis circuit involving in memory retrieval of vicarious fear conditioning</b>	15:55 - 15:55

Speaker: Yi-Han Liao (Chiayi City, Taiwan)

**Nucleoporin POM121 confer passive nuclear translocation and envelop integrity via Sigma-1 receptor in poly-PR-induced C9orf72 ALS** 15:55 - 15:55

Speaker: Hsiang-En Wu (Baltimore, United States)

**Distinct effects of synthetic GPR17 antagonists on cellular signaling in recombinant HEK293 cells and native oligodendroglial cell backgrounds** 15:55 - 15:55

Speaker: Jack McDonald (Melbourne, Australia)

**Stress and Airborne Oxytocin Effects on Male Mice' Sex Motives** 15:55 - 15:55

Speaker: Li-Han Sun (Tainan, Taiwan)

**Dietary cuprizone and gestational THC exposure both induce localized depletion of brain copper** 15:55 - 15:55

Speaker: Brittney Lins (Bentley, Australia)

**A multiverse meta-analysis of oxytocin administration studies** 15:55 - 15:55

Speaker: Heemin Kang (Oslo, Norway)

**Chronic exposure to air pollutants leads to cognitive decline mediated by gut-derived metabolite TMAO in adult mice** 15:55 - 15:55

Speaker: Akhlaq Hussain (Kowloon, Hong Kong)

**Psychiatric risks of corticosteroids: findings from a systematic review and meta-analysis** 15:55 - 15:55

Speaker: Keisuke Kusudo (Tokyo, Japan)

**Barriers to international research in neuropsychopharmacology for early career researchers - preliminary data from the 1st CINP fellowship program survey** 15:55 - 15:55

Speaker: Gina M. Kemp (Montreal, Canada)

**Clinical Case Report of a Patient Admitted to a Psychiatric Emergency Unit in a Referral Hospital in a Southern State of Brazil, with First-Episode Psychosis** 15:55 - 15:55

**Sensitivity and specificity of anti-gliadin IgG antibodies for patients with gluten intolerance, and their psychiatric/physical symptoms** 15:55 - 15:55

Speaker: Mikuni Motoyama (Nishinomiya, Japan)

**Chronic morphine exposure alters the molecular cargo of brain-derived extracellular vesicles: upregulation of ARC and neuroplasticity-related proteins** 15:55 - 15:55

Speaker: Pedro Gobira (Aarhus, Denmark)

**Early assertive pharmacotherapy intervention study for stimulant associated psychosis—a 24-month prospective randomized controlled trial** 15:55 - 15:55

Speaker: Albert Kar Kin Chung (Hong Kong, Hong Kong)

**Secondary effects of psychopharmacological drugs as primary effects in forensic psychiatry. Based on the swiss model** 15:55 - 15:55

Speaker: Manola Schlemper (Windisch, Switzerland)

**Combined traditional Chinese and Western medicine reduces dementia risk in insomnia patients: a real-world cohort study** 15:55 - 15:55

Speaker: Yu-Ching Huang (Taipei, Taiwan)

**Large-scale profiling of coding and long noncoding transcriptomes in the hippocampus of mice acutely exposed to vaporized THC** 15:55 - 15:55

Speaker: Mi Ran Choi (Suwon, Korea, Republic of)

**The neurobiological foundation for physical exercise** 15:55 - 15:55

**recommendations in reducing symptoms of ADHD**

*Speaker:* Anna Szczegielniak (Katowice, Poland)

**How testosterone administration affects learning to avoid harm in healthy men: a double-blind, placebo-controlled study**

15:55 - 15:55

*Speaker:* Yin Wu (Hong Kong, Hong Kong)

**Systematic review of the role of gut microbiota in the pathophysiology of ADHD and the potential of probiotic strains for the management of ADHD symptoms**

15:55 - 15:55

*Speaker:* Adicitra Auriel Bestari (Surabaya, Indonesia)

*Break*

15:55 - 16:35

SR

**Afternoon Coffee Break**

*Plenary*

16:35 - 17:35

PL

**Plenary 3: Keynote Lecture Paul Kenny**

*Chair:* Atsumi Nitta (Japan)

*Chair:* Lih-Chu Chiou (Taipei, Taiwan)

**Cellular mechanisms of nicotine craving**

16:35 - 17:35

*Speaker:* Paul Kenny (New York, United States)

*Session*

17:40 - 18:40

PL

**AsCNP Symposium: The third survey of the Research in East Asia Psychotropic Prescription Patterns on Antidepressants**

*Chair:* Shih-Ku Lin (Taipei, Taiwan)

**Polypharmacy and Prescription Patterns of Antidepressants in REAP AD3**

17:40 - 18:00

*Speaker:* Tian-Mei Si (Beijing, China)

**Diagnostic Distribution of Antidepressant Users: Findings from the REAP-AD3**

18:00 - 18:20

*Speaker:* Yueh-Pin Lin (Taipei, Taiwan)

**Current Trend of the Patterns of Antidepressants in Asian Countries: Evidence from REAP-AD3**

18:20 - 18:40

*Speaker:* Takahiro A. Kato (Hokkaido, Japan)

*Spotlight Session*

17:40 - 18:40

S1

**Spotlight Session 3: Many Faces of Limbic Encephalitis**

*Chair:* Anna Lizza Mañalac (Pampanga, Philippines)

**Autoimmune Mechanisms and Antibody Profiling in Limbic Encephalitis**

17:40 - 17:55

*Speaker:* Arnold Angelo Pineda (Philippines)

**Psychiatric Manifestations of Limbic Encephalitis: Neuropsychopharmacological Perspectives**

17:55 - 18:10

*Speaker:* Johnny Lokin (Philippines)

**Therapeutic Strategies: Immunomodulation and Beyond**

18:10 - 18:25

*Speaker:* Celeste Pena (Philippines)

**Cognitive and Behavioral Sequelae of Limbic Encephalitis**

18:25 - 18:40

*Speaker:* Roberto Bolivar Capistrano (Philippines)

*Featured Communication*

17:40 - 18:40

S2

**Featured Communication 3: Dopamine/Schizophrenia**

*Chair:* Anthony Grace (Pittsburgh, United States)

**Leveraging digital enablers to amplify the evidence for clinical practice in treatment-resistant schizophrenia**

17:40 - 17:55

*Speaker:* Kannan Subramaniam (Auckland, New Zealand)

**Nitrous oxide exerts rewarding effect via regulating D1 receptor and BDNF pathway in ventral tegmental area-nucleus accumbens dopamine circuit**

17:55 - 18:10

*Speaker:* Zhang-Jin Zhang (Hong Kong, Hong Kong)

**Raloxifene induces sex-specific changes in anxiety- and dopamine-related behaviours in adolescent offspring following prenatal immune activation**

18:10 - 18:25

*Speaker:* Tertia Purves-Tyson (Sydney, Australia)

**Q&A, Discussion**

18:25 - 18:40

*Networking*

17:40 - 19:40

S3

**Japan Networking Reception**

*Selected Colloquium*

17:40 - 18:40

M1

**Selected Colloquium 2: Adverse events: a neglected area in pharmacotherapeutics**

*Chair:* Siegfried Kasper (Vienna, Austria)

**Adverse effects and the treatment of resistant depression**

17:40 - 18:00

*Speaker:* Gabriella Gobbi (Montreal, Canada)

**Are side effects necessary for antidepressive treatment: the Psilocybin experience**

18:00 - 18:20

*Speaker:* Siegfried Kasper (Vienna, Austria)

**The WPA/CINP study on Tool development for Psychosis (WPA/CINP TOP study): rational and design**

18:20 - 18:40

*Speaker:* Konstantinos Fountoulakis (Thessaloniki, Greece)

*Meet the Experts / Campfire Session*

17:40 - 18:40

M2

**Meet the Expert 3: Bipolar Disorder (LIMITED SEATS)**

*Chair:* Philip Mitchell (Australia)

**Bipolar Disorder: Case Discussions**

17:40 - 18:40

*Speaker:* Allan Young (London, United Kingdom)

*Speaker:* Michael Berk (Geelong, Australia)

*Speaker:* Philip Mitchell (Australia)



## Tuesday, 17. June 2025

### Sponsored Symposium

08:00 - 09:00

S2

### Sponsored Breakfast Symposium

### Plenary

09:10 - 10:10

PL

### Plenary 4: Keynote Lecture Susan Shur-Fen Gau

Chair: Andi Tanra (Makassar, Indonesia)

Chair: Lukoye Atwoli (Kenya)

### Plenary Lecture 4: Characterizing Attention-deficits Hyperactivity Disorder: Insights from Neurocognition, Imaging, Pharmacotherapy, and the Gut-Brain Axis

09:10 - 10:10

Speaker: Susan Shur-Fen Gau (Taipei, Taiwan)

### Networking

09:30 - 17:00

SR

### OPEN: Exhibition & CINP Members' Lounge

### Break

10:10 - 10:50

SR

### Morning Coffee Break

### Posters

10:15 - 10:45

EXH

### Poster Session 3: Bipolar Disorders, OCD, PTSD, Variable

Chair: Shao-Han Chang (Taipei, Taiwan)

### Exacerbation of brain stress-related inflammation associated with disruption of inflammatory suppression mechanisms in hypothalamic microglia under conditions of cancer cachexia

10:15 - 10:15

Speaker: Yukari Suda (Tokyo, Japan)

### Assessment of the impact of premorbid traits on allostatic load of caregivers

10:15 - 10:15

Speaker: Carolina Remedi (Cordoba, Argentina)

### Discrimination Between Healthy Participants and People with Panic Disorder Based on Polygenic Scores for Psychiatric Disorders and for Intermediate Phenotypes using Machine Learning

10:15 - 10:15

Speaker: Kazutaka Ohi (Gifu, Japan)

### A Single Yoga Session for Anxiety and Stress in Adults with or without Mental Illnesses: A Scoping Review

10:15 - 10:15

Speaker: Saeko Ikai-Tani (Tokyo, Japan)

### Preliminary study on visuospatial impairment examined by eye tracking in patients with Obsessive-Compulsive Disorder

10:15 - 10:15

Speaker: Yukihiro Hosoi (Hyogo, Japan)

### Comparison of the efficacy and tolerability between paroxetine and escitalopram in patients with Obsessive-Compulsive Disorder in real-world clinical settings in Japan

10:15 - 10:15

Speaker: Keiichiro Mukai (Nishinomiya, Japan)

### A rapid clinical response to etifoxine in treatment-resistant obsessive-compulsive disorder: A case report and literature review

10:15 - 10:15

Speaker: Pornjira Pariwatcharakul (Bangkok, Thailand)

<b>Exploring functional connectivity in anxiety: the role of the hippocampus, insula, and amygdala during a ketamine infusion</b>	10:15 - 10:15
<i>Speaker:</i> Samantha Graf (Vienna, Austria)	
<b>Focus on orexin-A in obese diabetes rats: upregulation of orexin-A receptor in the diabetic brain</b>	10:15 - 10:15
<b>Using spatially resolved single-nucleus multi-omics approach to understand how adversity contributes to psychiatric disorders</b>	10:15 - 10:15
<i>Speaker:</i> Tamim Ahsan (Wollongong, Australia)	
<b>Lipid core-encapsulated cannabidiol causes anxiolytic- and panicolytic-like effects on defensive behavior elicited in mice by <i>Bothrops jararaca</i> lancehead pit vipers</b>	10:15 - 10:15
<i>Speaker:</i> Norberto Cysne Coimbra (Ribeirão Preto, Brazil)	
<b>Accelerated brain aging in young women with post-traumatic stress disorder</b>	10:15 - 10:15
<i>Speaker:</i> Yoonji Joo (Seoul, Korea, Republic of)	
<b>Development of key components in a small, portable device for the therapeutic monitoring of lithium</b>	10:15 - 10:15
<i>Speaker:</i> Seetal Dodd (Geelong, Australia)	
<b>C-reactive protein and response to add-on dextromethorphan treatment in bipolar disorders: Results from a placebo-controlled trial</b>	10:15 - 10:15
<i>Speaker:</i> Chih-Chun Huang (Tainan, Taiwan)	
<b>Distinctive association patterns between topological properties of brain structural networks and social cognition in euthymic bipolar disorder</b>	10:15 - 10:15
<i>Speaker:</i> Tsai Chung Hahn (Tainan, Taiwan)	
<b>Altered prefrontal cortex-based functional connectivity and trait impulsivity among patients with bipolar disorder and history of suicide attempts</b>	10:15 - 10:15
<i>Speaker:</i> Mao-Hsuan Huang (Taipei, Taiwan)	
<b>Differentially expressed platelet oncoproteins and their association with plasma Programmed cell death ligand 1 in bipolar manic patients</b>	10:15 - 10:15
<i>Speaker:</i> Li Jhang (Taipei City, Taiwan)	
<b>Dynamic Postural Control in remitted Bipolar I Disorder: A CDP study</b>	10:15 - 10:15
<i>Speaker:</i> Abubacker Rahina (Bengaluru, India)	
<b>Effectiveness of long-acting injectable aripiprazole on relapse prevention of bipolar I disorder</b>	10:15 - 10:15
<i>Speaker:</i> Chiao-Hsin Yen (Debrecen, Hungary)	
<b>Cognitive inflexibility associated with decline deviation from fNIRS-measured brain function in mood disorders</b>	10:15 - 10:15
<i>Speaker:</i> Yun-Hsuan Chang (Tainan, Taiwan)	
<b>Delayed onset post-stroke mania, a case report and literature review</b>	10:15 - 10:15
<i>Speaker:</i> Jason Hong-Yi Chang (Taipei, Taiwan)	
<b>Therapeutic drug monitoring for antipsychotic medication to estimate drug adherence in Japanese patients with psychiatric disorders</b>	10:15 - 10:15
<i>Speaker:</i> Wataru Tanichi (Gifu, Japan)	
<b>Risk of agranulocytosis and neutropenia in patients with</b>	10:15 - 10:15

**Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis**

*Speaker:* Nahathai Limveeraprajak (Bangkok, Thailand)

**Psychotropics use and occurrence of falls in hospitalized patients: a matched case-control study**

10:15 - 10:15

*Speaker:* Chihiro Morishita (Tokyo, Japan)

**Epigenetic Insights into Social Cognition: Sex-Specific Influences of BDNF and Oxytocin Receptor Gene Methylation**

10:15 - 10:15

*Speaker:* Hye Yoon Park (Yongin, Korea, Republic of)

**The preliminary analysis of yoga therapy on burnout among medical staff: A single-arm pre-post intervention**

10:15 - 10:15

*Speaker:* Saeko Ikai-Tani (Tokyo, Japan)

**Lorazepam and survival in patients with pancreatic cancer: a retrospective cohort study**

10:15 - 10:15

*Speaker:* Jin Woo Park (Seoul, Korea, Republic of)

**Neuropsychologically-Based Clustering of Psychosomatic Patients**

10:15 - 10:15

*Speaker:* Tzu-Ting Chen (Douliu, Taiwan)

**A randomised controlled trial of an AI-enabled mental health intervention for generalized anxiety disorder symptoms**

10:15 - 10:15

*Speaker:* Allan Young (London, United Kingdom)

**Changes in peripheral immune functions including immune Checkpoint Systems by directly activating stress-responsive neurons**

10:15 - 10:15

*Speaker:* Kensuke Yamashita (Tokyo, Japan)

**Investigating associations between BDNF, cortisol, and cognitive performance during psychosocial and heat stress**

10:15 - 10:15

*Speaker:* Jonathan Flintoff (Brisbane, Australia)

**EL mouse as an animal model for epilepsy, anxiety and hyperactivity: involvement of Translocator Protein 18 kD (TSPO)**

10:15 - 10:15

*Speaker:* Yurie Nakamoto (Tokyo, Japan)

**Effects of social jetlag on the different risk of anxiety between women and men: insights from the Taiwan biobank project**

10:15 - 10:15

*Speaker:* Min-Chiao Chang (Taipei, Taiwan)

**Socioeconomic adversity, maternal nutrition, and the prenatal programming of child cognition and language at two years of age through maternal inflammation**

10:15 - 10:15

*Speaker:* Andrea Gogos (Parkville, Australia)

**Psychosocial function and prescribed psychotropic medication in 269 Chinese adults with common mental disorders (CMD) over 9-year follow up**

10:15 - 10:15

*Speaker:* Linda CW Lam (Hong Kong, Hong Kong)

*Special Format*

10:50 - 11:50

PL

**Medical Legalization of Psychedelics: An International Perspective**

*Chair:* Allan Young (London, United Kingdom)

**Medical Legalization of Psychedelics: An International Perspective**

10:50 - 11:50

*Speaker:* Ilan Hayman (Melbourne, Australia)

*Speaker:* Scott Edwards (Melbourne, Australia)

*Speaker:* Lauren Macdonald (Melbourne, Australia)

*Speaker:* Gabriella Gobbi (Montreal, Canada)

*Speaker:* Guy Goodwin (Oxford, United Kingdom)

*Symposium*

10:50 - 12:05

S1

**Symposium 8: From Molecular Mechanisms to Brain Circuitries: How Psychedelics are Reshaping Our Understanding of Neuropsychiatric and Behavioral Disorder Treatments**

*Chair:* Danilo De Gregorio (Milan, Italy)

**Molecular and cellular mechanisms of the long-lasting effects of psychedelics and their non-hallucinogenic derivatives** 10:50 - 11:15

*Speaker:* Argel Aguilar-Valles (Ottawa, Canada)

**Toward an understanding of the therapeutically relevant mechanisms of psilocybin for anorexia nervosa** 11:15 - 11:40

*Speaker:* Claire Foldi (Clayton, Australia)

**A single dose of lysergic acid diethylamide (LSD) reduces alcohol consumption and reverts dopaminergic (DA) dysfunction in male mice** 11:40 - 12:05

*Speaker:* Danilo De Gregorio (Milan, Italy)

*Symposium*

10:50 - 12:05

S2

**Symposium 9: The Role of Biomarkers in The Development of More Personalized and Effective Treatments for Psychiatric Disorders**

*Chair:* Magdalene de Rozario (Melbourne, Australia)

**A systematic review of neuroimaging biomarkers to predict antipsychotic treatment response** 10:50 - 11:15

*Speaker:* Magdalene de Rozario (Melbourne, Australia)

**Inflammation and aging in psychosis - a transdiagnostic proteomics study using the Human Connectome Project for Early Psychosis (HCP-EP)** 11:15 - 11:40

*Speaker:* Moritz Haaf (Boston, United States)

**Biological aging indicators in stress-related disorders: a (neuro)biological perspective on lifestyle interventions in psychiatric practice** 11:40 - 12:05

*Speaker:* Laura Han (Amsterdam, Netherlands)

*Symposium*

10:50 - 12:05

S3

**Symposium 7: Susceptibility in the Developing Brain: Why the Timing of Insults and Sex Matter**

*Chair:* Felipe Gomes (Ribeirao Preto, Brazil)

**Roles of dark microglia during development in health and maternal immune activation** 10:50 - 11:15

*Speaker:* Marie-Eve Tremblay (Victoria, Canada)

**Peripubertal stress exerts differential impacts on thalamic reticular and reuniens nuclei in male vs female rats** 11:15 - 11:40

*Speaker:* Anthony Grace (Pittsburgh, United States)

**The protective role of perineuronal nets against stress** 11:40 - 12:05

*Speaker:* Felipe Gomes (Ribeirao Preto, Brazil)

*Data Blitz Session*

10:50 - 12:05

M1

**Data Blitz 4: Depression treatment**

*Chair:* Bernhard Baune (Münster, Germany)

**Effectiveness of transcranial pulse stimulation for major depression: preliminary evidence for clinical response and neuroimaging mechanisms** 10:50 - 10:56

Speaker: Penny Ping Qin (Hong Kong, Hong Kong)

**Association of TMS-induced cortical hemodynamic responses with relapse vulnerability in patients with major depressive disorder** 10:56 - 11:02

Speaker: Minxia Jin (Hong Kong, China)

**Patient and clinician acceptance of recent technological advances in the therapeutic monitoring of lithium** 11:02 - 11:08

Speaker: Seetal Dodd (Geelong, Australia)

**CT-152, a prescription digital therapeutic for Major depressive disorder: a real-world analysis of durability of treatment effect** 11:08 - 11:14

Speaker: Jeffrey Cochran (Princeton, United States)

**A Genetically Informed Approach to Antidepressant Prescription for Youth with Major Depressive Disorder** 11:14 - 11:20

Speaker: Bradley Roberts (Perth, Australia)

**Antidepressant activity of strategic electrical stimulation of prefrontocortical neurons primed for excitability** 11:20 - 11:26

Speaker: Francis Bambico (St. John's, Canada)

**Ethnic variability in rTMS dosage: A call for adaptive therapeutic innovation** 11:26 - 11:32

Speaker: Bella B.B. Zhang (Hung Hum, Hong Kong)

**A new chronic dizziness disease: persistent postural-perceptual dizziness (PPPD) and vortioxetine** 11:32 - 11:38

Speaker: Kensuke Kiyomizu (Nobeoka, Miyazaki, Japan)

**Discussion, Q&A** 11:38 - 12:05

*Selected Colloquium*

10:50 - 11:50

M2

**Selected Colloquium 9: Recent Advances in Obsessive Compulsive Disorder (OCD)**

Chair: Mohandas Warriar (Trichur, India)

**Circuits and Networks in OCD** 10:50 - 11:10

Speaker: Mohandas Warriar (Trichur, India)

**Evaluating OCD circuits with non-invasive neuromodulation: investigative and therapeutic studies** 11:10 - 11:30

Speaker: Janardhanan Narayanaswamy (Geelong, Australia)

**The 3S of pharmacological treatment for OCD (SRIs, super-doses, safety) - 2025 update** 11:30 - 11:50

Speaker: Joseph Zohar (Ramat Gan, Israel)

*Spotlight Session*

12:15 - 13:15

PL

**Spotlight Session 4: Women in Neuropsychopharmacology**

Chair: Gabriella Gobbi (Montreal, Canada)

Chair: Susan Shur-Fen Gau (Taipei, Taiwan)

**Women in Neuropsychopharmacology** 12:15 - 12:45

Speaker: Lianne Schmaal (Melbourne, Australia)

**Women in Neuropsychopharmacology: Discussion** 12:45 - 13:15

Speaker: Ya Mei Bai (Taipei, Taiwan)

Speaker: Lucie Bartova (Vienna, Austria)

Speaker: Kim Q. Do (Lausanne, Switzerland)

Speaker: Atsumi Nitta (Japan)

Speaker: Tian-Mei Si (Beijing, China)

*Featured Communication*

12:15 - 13:15

S1

**Featured Communication 4: Schizophrenia/Clinical**

*Chair:* Young-Chul Chung (Jeonju, Korea, Republic of)

**A population-based study on long-term mortality risk associated with clozapine use among patients with schizophrenia**

12:15 - 12:30

*Speaker:* Sherry Kit Wa Chan (Hong Kong, Hong Kong)

**Targeting microglial activation in schizophrenia: a longitudinal [18F]DPA-714 PET imaging study investigating the effects of a 3-month treatment with natalizumab - \*\*Rafaelsen Young Investigators Award 2025\*\***

12:30 - 12:45

*Speaker:* Yuya Mizuno (London, United Kingdom)

**A novel graph theory-driven application of <sup>18</sup>F-FDG-PET with antipsychotic dose correction and a machine learning approach to capture discrete brain metabolic connectivity in treatment-resistant schizophrenia**

12:45 - 13:00

*Speaker:* Andrea de Bartolomeis (Napoli, Italy)

**Q&A, Discussion**

13:00 - 13:15

*Session*

12:15 - 13:15

S2

**NbN Updates: NbN for patients & families (NbNpf); Different Dose, Different Pharmacology concept (DDDP)**

*Chair:* Joseph Zohar (Ramat Gan, Israel)

**Introduction and update on NbN in 2025**

12:15 - 12:30

*Speaker:* Joseph Zohar (Ramat Gan, Israel)

**Different Dose, Different Pharmacology (DDDP)**

12:30 - 12:45

*Speaker:* Pierre Blier (Ottawa, Canada)

**Challenges and opportunities in integrating serotonergic agonists ("psychedelics") into NbN**

12:45 - 13:00

*Speaker:* Guy Goodwin (Oxford, United Kingdom)

**Discussion and Q&A**

13:00 - 13:15

*Speaker:* Hiroyuki Uchida (Japan)

*Selected Colloquium*

12:15 - 13:15

S3

**Selected Colloquium 3: Targeting NMDA Receptors Mediate Neuron-Glia Interactions for the Treatment of Neuropsychiatric Disorders: From Basic Research to Application**

*Chair:* Wen-Sung Lai (Taipei, Taiwan)

**Modulation of brain functions by glial reset**

12:15 - 12:35

*Speaker:* Schuichi Koizumi (Yamanashi, Japan)

**The role of glial phagocytosis in multiple sclerosis**

12:35 - 12:55

*Speaker:* Jungjoo Park (Daejeon, Korea, Republic of)

**Key molecules for neuron-glia Interactions during stress: Role of neurotransmitters**

12:55 - 13:15

*Speaker:* Tomoko Soga (Selangor Darul Ehsan, Malaysia)

*Data Blitz Session*

12:15 - 13:15

M1

**Data Blitz 5: Psychedelic/ketamine-related**

*Chair:* Argel Aguilar-Valles (Ottawa, Canada)

<b>The mGluR2/3 antagonist enhances the behavioral and cellular antidepressant-like effects of psilocybin and scopolamine</b>	12:15 - 12:21
<i>Speaker:</i> Andrzej Pilc (Krakow, Poland)	
<b>Mapping neuronal ensemble activity in the mouse prefrontal cortex during motivational control of behavior following ketamine treatment</b>	12:21 - 12:27
<i>Speaker:</i> Jess Nithianantharajah (Parkville Victoria, Australia)	
<b>Psilocybin assisted psychotherapy for obsessive compulsive disorder, body dysmorphic disorder, and anorexia nervosa: study protocol</b>	12:27 - 12:33
<i>Speaker:</i> Nicola Acevedo (Melbourne, Australia)	
<b>Elucidating NMDA Receptor Hypofunction using Simultaneous EEG-fMRI Measures of Ketamine-Induced Neural Dynamics</b>	12:33 - 12:39
<i>Speaker:</i> Moritz Haaf (Boston, United States)	
<b>Psilocybin with Psychotherapeutic Support for Treatment-Resistant Depression: A Pilot Clinical Trial</b>	12:39 - 12:45
<i>Speaker:</i> Sally Meikle (Melbourne, Australia)	
<b>Using Classification and Regression Tree Modelling to Investigate Low-Dose Ketamine's Effect on Remission of Suicidal Symptoms Among Patients with Treatment-Resistant Depression and Strong Suicidal Thought</b>	12:45 - 12:51
<i>Speaker:</i> Ping Chung Wu (Taipei, Taiwan)	
<b>Therapeutic memory reconsolidation as a treatment for substance use disorders and how psychedelics are facilitating this intervention: The UNITY Study</b>	12:51 - 12:57
<i>Speaker:</i> Shelan Ofori (London, United Kingdom)	
<b>Acute and chronic psilocybin in mouse models of psychiatric disorders</b>	12:57 - 13:03
<i>Speaker:</i> Thibault Renoir (Melbourne, Australia)	
<b>Safety and ethical considerations for psychedelic assisted psychotherapy (PAP)</b>	13:03 - 13:09
<i>Speaker:</i> Susan Rossell (Melbourne, Australia)	
<b>Discussion, Q&amp;A</b>	13:09 - 13:15
<i>Selected Colloquium</i> 12:15 - 13:15	M2
<b>Selected Colloquium 8: Lithium: the latest news about the oldest drug in psychiatry</b>	
<i>Chair:</i> Marylou Selo (New York, United States)	
<b>"Getting old on the oldest drug" Ticking on Lithium Batteries for 45 years</b>	12:15 - 12:35
<i>Speaker:</i> Marylou Selo (New York, United States)	
<b>The eyes have it - lithium and neuroprotection in the brain and beyond</b>	12:35 - 12:55
<i>Speaker:</i> Janusz Rybakowski (Poznan, Poland)	
<b>Lithium: how low could we go?</b>	12:55 - 13:15
<i>Speaker:</i> Allan Young (London, United Kingdom)	
<i>Break</i> 13:15 - 14:40	SR
<b>Lunch Break</b>	
<b>Test Confirmation</b>	13:15 - 13:25

Speaker: Oswin Lohne (Hann, Germany)

*Sponsored Symposium*

13:25 - 14:25

S1

**Sponsored Lunch Symposium**

*Posters*

13:25 - 13:55

EXH

**Poster Session 4: Childhood & Adolescent Disorders, ADHD, Dementia, Epilepsy, Pain, Variable**

Chair: Lianne Schmaal (Melbourne, Australia)

**Role of the anterior insula and the endocannabinoid system in Autism neurodevelopmental disorder**

13:25 - 13:25

Speaker: Elena Martín García (Barcelona, Spain)

**Therapeutic potential of low-dose opioids through brain region-specific neural activation for autism spectrum disorder**

13:25 - 13:25

Speaker: Rei Yokoyama (Hiroshima, Japan)

**Developmental inhibition of Purkinje cells causes male-specific ASD-like phenotypes - vulnerable male cerebellum hypothesis**

13:25 - 13:25

Speaker: Satoshi Kamijo (Tokyo, Japan)

**$\alpha 6$ GABA<sub>A</sub> receptor-selective positive allosteric modulator as a potential therapy for autism: A preclinical study in Fmr1 KO mice**

13:25 - 13:25

Speaker: Yu-Hsuan Lee (Taipei, Taiwan)

**A Genome-Wide Association Study of Autistic Traits and Neurocognitive Function in Autism**

13:25 - 13:25

**Effects of low dose valproic acid on sleep disorders in autism spectrum disorder**

13:25 - 13:25

Speaker: Eiji Nakagawa (Tokyo, Japan)

**The Relationship Between Genetic Liability of Autism Associated Co-Occurring Conditions and Clinical Severity and Neurocognitive Function in Autism**

13:25 - 13:25

**Does prenatal exposure to low-dose di-2-ethylhexyl phthalate impair neurodevelopment in a Val66Met BDNF mouse model?**

13:25 - 13:25

Speaker: Alicia Bjorksten (Melbourne, Australia)

**A Novel Diathesis-Stress Model of Commonly Comorbid Early Onset Psychiatric Disorders**

13:25 - 13:25

Speaker: Charlotte Caswell (Montreal, Canada)

**Role of attention deficit hyperactivity disorder and major depressive disorder on executive dysfunction and appetite hormone dysregulation and proinflammatory cytokines among adolescents with death ideation**

13:25 - 13:25

Speaker: Jia Shyun Jeng (Taipei, Taiwan)

**Cannabidiol mitigates cognitive deficits in a mouse model of Alzheimer's disease**

13:25 - 13:25

Speaker: Yi-Chia Chen (Tainan, Taiwan)

**RX 821002, an  $\alpha 2$  adrenoceptor antagonist, enhances acetylcholine efflux in the nucleus accumbens of freely moving rats following intra-accumbal and systemic administration**

13:25 - 13:25

Speaker: Kazuki Arai (Chiba, Japan)

**Cannabigerol Reduces Neurodegeneration and Attenuates Glial Response in the Hippocampus of Mice with Transient Global Cerebral Ischemia**

13:25 - 13:25



<b>Protective effects of Shati/Nat8l on A<math>\beta</math> neurotoxicity in the cultured Neuro-2a cells</b>	13:25 - 13:25
<i>Speaker:</i> Miho Takakuwa (Toyama City, Japan)	
<b>Decreased brain pH correlated with progression of Alzheimer's disease neuropathology: a systematic review and meta-analyses of postmortem studies</b>	13:25 - 13:25
<i>Speaker:</i> Hideo Hagihara (Toyoake, Japan)	
<b>Cognitive flexibility as a possible index of age-related cognitive decline</b>	13:25 - 13:25
<i>Speaker:</i> Masaki Kakeyama (Tokorozawa, Japan)	
<b>Genome-wide association study of frailty in middle-aged adults: insights from ZNF552 rs2288538 variant</b>	13:25 - 13:25
<i>Speaker:</i> Tung-Hsia Liu (Miaoli County, Taiwan)	
<b>Glycosylation modifications correlating with plasma CCL11 elevation in patients with moderate dementia</b>	13:25 - 13:25
<i>Speaker:</i> Yu-Li Liu (Miaoli County, Taiwan)	
<b>Effects of 24-month supplementation of EPA and dha on hippocampal spontaneous neuroactivity in mild cognitive impairment and dementia: a resting-state fMRI study</b>	13:25 - 13:25
<i>Speaker:</i> Chen-Chia Lan (Taichung, Taiwan)	
<b>Theoretical drug selection for BPSD</b>	13:25 - 13:25
<i>Speaker:</i> Shuji Iritani (Toyoake, Japan)	
<b>Unveiling the Cognitive Enhancing Effects of RS-D7, a Novel NMDAR Modulator, on Hippocampus-Dependent Learning and Memory in Mice</b>	13:25 - 13:25
<i>Speaker:</i> Hsin-Ching Chien (Taipei, Taiwan)	
<b>Toxicity and metabolism of structurally similar fentanyl analogs with the integrated approach using <i>in vitro</i> experiments and <i>in silico</i> predictions</b>	13:25 - 13:25
<i>Speaker:</i> Ryo Hiramasa (Gifu, Japan)	
<b>The development of AUFEL: culture-centered executive function measurement tools for Indonesian children and adolescents</b>	13:25 - 13:25
<i>Speaker:</i> Suzy Yusna Dewi (Jakarta, Indonesia)	
<b>Changes in decision making behavior between pregnancy and postpartum</b>	13:25 - 13:25
<i>Speaker:</i> M. Mercedes Perez-Rodriguez (New York, United States)	
<b>Exploring the Association Between Prenatal SARS-CoV-2 Infection, Placental Immune and Inflammatory Gene Expression and Postpartum Depression with a Validation Analysis</b>	13:25 - 13:25
<i>Speaker:</i> M. Mercedes Perez-Rodriguez (New York, United States)	
<b>The role of neutrophil myeloperoxidase and the neuronal injury marker neurofilament light chain in COVID-19 infected patients</b>	13:25 - 13:25
<i>Speaker:</i> Shu Chih Liu (Miaoli, Taiwan)	
<b>Regulatory mechanism of astrocytic glutamine synthetase expression in epileptic brain via Hippo-YAP pathway</b>	13:25 - 13:25
<i>Speaker:</i> Yusuke Nasu (Niigata, Japan)	
<b>The role of ANT in modulating hippocampal oscillations in animal models of epilepsy</b>	13:25 - 13:25
<i>Speaker:</i> Yu-Chieh Huang (Tainan, Taiwan)	
<b>Are Persistent Somatic Symptoms a Trans-Diagnostic Concept? A cluster analysis</b>	13:25 - 13:25

Speaker: Wei-Lieh Huang (Douliu, Taiwan)

**The relieving effect of activating the pleasure center VTA on chronic stress-induced hyperalgesia** 13:25 - 13:25

Speaker: An-Chi Hsu (Tainan, Taiwan)

**Effect of cannabinoid CB2 agonist on cold hypersensitivity in mice with post-traumatic trigeminal neuropathy** 13:25 - 13:25

Speaker: Simeng Ma (Hiroshima, Japan)

**Enhancement of *in vivo* dopamine efflux in the rat nucleus accumbens by orexin OX<sub>2</sub> receptor blockade is reduced in two chronic pain models** 13:25 - 13:25

Speaker: Tadashi Saigusa (Matsudo, Japan)

**Glutamate, glutamine, and GABA levels in adults with autism spectrum disorder: a 7T MRS study** 13:25 - 13:25

Speaker: Manabu Kubota (Chiba, Japan)

**Exploring the dynamics of L1 retrotransposition in natural aging: Insights from the mouse model** 13:25 - 13:25

Speaker: Chu Guo (Kumamoto, Japan)

**Neuropsychiatric symptoms as predictors for cognitive impairment and revert factors for normal cognition: a one-year prospective cohort study** 13:25 - 13:25

Speaker: Daochompu Nakawiro (Bangkok, Thailand)

**DNMT1 complex disorders: neurodegeneration from a specific DNA methylation defect. The mutation knock in mouse model present similar to clinical form of HSN1E** 13:25 - 13:25

Speaker: Kaori Hojo (Hyogo Prefect, Japan)

#### Posters

13:55 - 14:25

EXH

#### Poster Session 5: Depression

Chair: Pierre Blier (Ottawa, Canada)

**M6A-mediated epitranscriptomic modifications in depression** 13:55 - 13:55

Speaker: Yogesh Dwivedi (Birmingham, United States)

**Differential effects of Psilocybin and Lisuride on Serotonin and Dopamine neuronal activity and behavior** 13:55 - 13:55

Speaker: Gabriella Gobbi (Montreal, Canada)

**L655,708 a negative allosteric modulator at of GABA<sub>A</sub> receptor increased dopamine neuronal activity up to 1 week after a single injection** 13:55 - 13:55

Speaker: Pierre Blier (Ottawa, Canada)

**The inhibitory effect of ifenprodil on nicotine-induced addictive behaviors** 13:55 - 13:55

Speaker: Soichiro Ide (Tokyo, Japan)

**Increase of the AMPA-evoked response in prefrontal cortex pyramidal neurons following acute administration of ketamine and S-ketamine in rats** 13:55 - 13:55

Speaker: Pierre Blier (Ottawa, Canada)

**5-HT<sub>2B</sub> receptors modulate the antidepressant-like response of the psychedelic LSD in rat but not in mice** 13:55 - 13:55

Speaker: Nasser Haddjeri (Bron, France)

**Using the live rat stress paradigm to investigate approach-avoidance behaviour relevant to psychiatric disorders** 13:55 - 13:55

Speaker: Jacqueline Iredale (Newcastle, Australia)

**Modulation of the endocannabinoid system by (S)-ketamine in an animal model of depression** 13:55 - 13:55

Speaker: Nicole Silva (Aarhus, Denmark)

**Knockdown of connexin43 in astrocytes is involved in the therapeutic effect of tricyclic antidepressant amitriptyline** 13:55 - 13:55

Speaker: Nozomi Tokunaga (Hiroshima, Japan)

**Discovering markers of intron retention in depression and its response to ketamine** 13:55 - 13:55

Speaker: Norihiro Okada (Tokyo, Japan)

**Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the triple reuptake inhibitor JS1-1-01 to determine the recommended phase II dose** 13:55 - 13:55

Speaker: Zhiwei Huang (Shanghai, China)

**Common and distinct effects of 10-hz rTMS and iTBS on striatum-based functional connectivity in major depressive disorder: a sham-controlled study** 13:55 - 13:55

Speaker: Cheng-Ta Li (Taipei, Taiwan)

**Anxiety behavior and immune response of microglia in rats subjected to stress through the sympathetic nervous system** 13:55 - 13:55

Speaker: Akihito Uezato (Tochigi, Japan)

**The Role of Gut Microbiome Levels in Depressive Disorder as a Psychological Indicator A Systematic Review for Malnutrition Prevention and Increased Risk of Metabolic Diseases** 13:55 - 13:55

**A multicenter clinical trial of Shuganjiyu capsules combined with Fluoxetine in the treatment of depression** 13:55 - 13:55

Speaker: Jitao Li (Beijing, China)

**Development of metabolomic biomarker signatures and diagnostic models for major depressive disorder using multiple supervised learning methods** 13:55 - 13:55

Speaker: Shen He (Shanghai, China)

**Exploring the subjective experience of patients with treatment-resistant depression on the effects of Esketamine Nasal Spray** 13:55 - 13:55

Speaker: Giovanni Martinotti (Chieti, Italy)

**Effects of low-dose naltrexone on salience network connectivity in major depressive disorder** 13:55 - 13:55

Speaker: Ben Moloney (Auckland, New Zealand)

**Does Excitatory/Inhibitory Balance Predict Ketamine Response in Treatment-Resistant Depression?: A Double-Blind Randomized Controlled Trial with <sup>1</sup>H-MRS** 13:55 - 13:55

Speaker: Yohei Ohtani (Tokyo, Japan)

**Age-specific variations in antidepressant efficacy of transcranial magnetic stimulation for treatment-resistant depression: a real-world retrospective study** 13:55 - 13:55

Speaker: Jia Shyun Jeng (Taipei, Taiwan)

**Longitudinal follow-up study of mood symptom rating, suicidality, psychological and physical health and quality of life post-rTMS in the refractory depressed patients in Taiwan** 13:55 - 13:55

Speaker: Tung-Ping Su (Taipei, Taiwan)

**The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: a** 13:55 - 13:55

<b>52-Week double-blind, placebo-controlled trial</b>		
Speaker:	Yingchih Cheng (Zhubei City, Taiwan)	
	<b>Predicting rTMS treatment response in depression: use of machine learning models to identify the roles of metabolic and clinical factors</b>	13:55 - 13:55
Speaker:	I Chun Liu (Tainan City, Taiwan)	
	<b>Screening and diagnosis of depression: Correlation of genomic alterations with functional magnetic resonance imaging</b>	13:55 - 13:55
Speaker:	Paramdeep Singh (Bathinda, India)	
	<b>Optimizing rTMS for depressive disorders: comparative efficacy and insights into clinical factors</b>	13:55 - 13:55
Speaker:	Chia-Hao Ma (Douliu City, Taiwan)	
	<b>Mapping peripheral molecular mechanisms associated with long-lasting effects of early life stress: a transcriptomic set-based approach</b>	13:55 - 13:55
Speaker:	Chiara Bottanelli (Milan, Italy)	
	<b>Clinical experiences with esketamine treatment at the department of psychiatry and psychological medicine, University Hospital Centre Zagreb, during the period from 2022 to 2024</b>	13:55 - 13:55
Speaker:	Maja Živković (Zagreb, Croatia)	
	<b>Association between endocrine disruptors and depressive symptoms among Taiwanese adolescents</b>	13:55 - 13:55
Speaker:	Yu-Hsin Huang (Taipei, Taiwan)	
	<b>Toward effective speech-based depression recognition: investigating data balance and depressive symptom severity in AI approaches</b>	13:55 - 13:55
Speaker:	Min Jhon (Gwangju, Korea, Republic of)	
	<b>Renin-angiotensin system in patients with major depressive disorder</b>	13:55 - 13:55
Speaker:	Chun-Hsin Chen (Taipei, Taiwan)	
	<b>Exploring LSD Microdosing in an open-label pilot for Major Depressive Disorder: The Interplay of Behavioral Activation, Mood Improvement, and Connectedness</b>	13:55 - 13:55
Speaker:	Carina Donegan (Auckland, New Zealand)	
	<b>Beyond the hype: examining the therapeutic potential of psychedelic microdosing through the lens of experimental control and evidence</b>	13:55 - 13:55
Speaker:	Orla Mallon (London, United Kingdom)	
	<b>Neural and behavioral evidence from reinforcement learning converge in support of relaxed beliefs under LSD</b>	13:55 - 13:55
Speaker:	Jonathan Kanen (New York, United States)	
	<b>Altered cerebral TSPO availability and functional connectivity in patients with major depressive disorder: a preliminary multimodal imaging study combining C-11 PK11195 PET and rs-fMRI</b>	13:55 - 13:55
Speaker:	Jong-Hoon Kim (Incheon, Korea, Republic of)	
	<b>Resting-state functional connectivity associations with suicidal ideation severity in treatment-resistant depression</b>	13:55 - 13:55
Speaker:	Patricia Burhunduli (Ottawa, Canada)	
	<b>Antidepressant use and antibiotics treatment failure</b>	13:55 - 13:55
Speaker:	Chi-Shin Wu (Zhunan, Taiwan)	
	<b>Optimizing sham control in transcutaneous auricular vagus nerve</b>	13:55 - 13:55

**stimulation for chronic insomnia: a pooled analysis from two randomized clinical studies**

*Speaker:* Zongshi Qin (Beijing, China)

*Symposium*

14:40 - 15:55

PL

**Symposium 10: Adversity and altered states? The neurobiological signature of early life adversity on the brain, and relevance to psychoactive drug responses**

*Chair:* Molly Carlyle (Oslo, Norway)

**Lifetime neural circuit and behavioral disruptions in a mouse model of childhood abuse**

14:40 - 15:05

*Speaker:* Erin Hisey (Boston, United States)

**Impacts of early life adversity on drug effects in healthy controls and substance use groups using acute and retrospective drug responses.**

15:05 - 15:30

*Speaker:* Molly Carlyle (Oslo, Norway)

**Differing responses to ketamine and MDMA in patients with and without early adversity: integrating clinical trial and naturalistic drug user findings**

15:30 - 15:55

*Speaker:* Celia J.A. Morgan (Exeter, United Kingdom)

*Symposium*

14:40 - 15:55

S1

**Symposium 11: Adult neurogenesis or de-differentiation regulate hippocampus plasticity in health and disease**

*Chair:* Maura Boldrini (New York, United States)

**A Baldwin interpretation of adult hippocampal neurogenesis: from functional relevance to physiopathology**

14:40 - 15:05

*Speaker:* Djohar Nora Arous (Bordeaux Cedex, France)

**Repetitive neuronal activations regulate cellular maturation state via nuclear reprogramming**

15:05 - 15:30

*Speaker:* Tsuyoshi Miyakawa (Toyoake, Japan)

**Molecular landscapes of hippocampal neurogenesis are disrupted in major depression**

15:30 - 15:55

*Speaker:* Maura Boldrini (New York, United States)

*Symposium*

14:40 - 15:55

S2

**Symposium 12: Reformulation, omics-based biomarkers and health economic implications of ketamine in the treatment of depression**

*Chair:* Bernhard Baune (Münster, Germany)

**Expanding access to ketamine through reformulation**

14:40 - 15:05

*Speaker:* Paul Glue (Otago, New Zealand)

**Discovery of omics-biomarkers of ketamine for treatment response in depression**

15:05 - 15:30

*Speaker:* Bernhard Baune (Münster, Germany)

**Economic evaluations of emerging pharmacological therapies for treatment resistant depression**

15:30 - 15:55

*Speaker:* Mary Lou Chatterton (Melbourne, Australia)

*Meet the Experts / Campfire Session*

14:40 - 15:40

S3

**Campfire Session: I Was So Much Older Then: Reflections on Research for Early Career Researchers (LIMITED SEATS)**

*Chair:* Allan Young (London, United Kingdom)

**I Was So Much Older Then: Reflections on Research for Early Career Researchers**

14:40 - 15:40

*Speaker:* Allan Young (London, United Kingdom)

*Speaker:* Gabriella Gobbi (Montreal, Canada)

*Speaker:* Michael Berk (Geelong, Australia)

*Selected Colloquium*

14:40 - 15:40

M1

**Selected Colloquium 4: Circuits driving drug taking: What insights for treatment do they hold?**

*Chair:* Jacqueline Iredale (Newcastle, Australia)

**A master regulator of opioid reward in the ventral prefrontal cortex**

14:40 - 15:00

*Speaker:* Paul Kenny (New York, United States)

**Sex differences in neural circuits driving binge drinking**

15:00 - 15:20

*Speaker:* Leigh Walker (Melbourne, Australia)

**Targeting the orexin (hypocretin) system to normalize sleep disturbances during cocaine abstinence**

15:20 - 15:40

*Speaker:* Morgan H. James (Camperdown, Australia)

*Spotlight Session*

14:40 - 15:40

M2

**Spotlight Session 5: Addiction and Mental Health**

*Chair:* Marco Leyton (Montreal, Canada)

**Addictions and Mental Health**

14:40 - 15:10

*Speaker:* Marco Leyton (Montreal, Canada)

**Discussion on Addictions**

15:10 - 15:40

*Speaker:* Guy Goodwin (Oxford, United Kingdom)

*Speaker:* Antonio Verdejo-Garcia (Melbourne, Australia)

*Speaker:* Marco Leyton (Montreal, Canada)

*Speaker:* Leah Mayo (Calgary, Canada)

*Break*

15:55 - 16:35

SR

**Afternoon Coffee Break**

*Featured Communication*

16:35 - 17:35

PL

**Featured Communication 5: Addiction/Cannabis**

*Chair:* Ming-Chyi Huang (Taipei, Taiwan)

**Pharmaco-omics of acamprosate treatment response: from clinical trial to biomarker discovery**

16:35 - 16:50

*Speaker:* Ming-Fen Ho (Rochester, United States)

**Insulin-like growth factor 1 in the brain and addiction --- the vulnerable prefrontal cortex in opioid use disorder - \*\*Rafaelsen Young Investigators Award 2025\*\***

16:50 - 17:05

*Speaker:* Zi-Jun Wang (Lawrence, United States)

**The Effects of Extended Cannabis Abstinence in Young Adults with Co-Occurring Cannabis Use Disorder and Major Depression**

17:05 - 17:20

*Speaker:* Tony George (Toronto, Canada)

**The effect of adolescent pre-treatment with the selective Cannabinoid 1 receptor agonist on hippocampal theta synchronization in adulthood**

17:20 - 17:35

*Speaker:* Bernat Kocsis (Boston, United States)

*Spotlight Session*

16:35 - 17:35

S1

**Spotlight Session 7: Frontiers of schizophrenia research in basic and clinical from JSNP and JSCNP**

*Chair:* Atsumi Nitta (Japan)

**Dopamine and Glutamate Hypotheses for Treatment Response in Schizophrenia**

16:35 - 16:55

*Speaker:* Yumina Nakane (Japan)

**Frontotemporal Network Deficits and Auditory Impairments of EGF-induced Animal Model for Schizophrenia**

16:55 - 17:15

*Speaker:* Hiroyuki Nawa (Wakayama, Japan)

**Mouse Phenotype-Driven Approach to Schizophrenia Research**

17:15 - 17:35

*Speaker:* Takao Keizo (Japan)

*Spotlight Session*

16:35 - 17:35

S2

**Spotlight Session 8: Recent advances in Alzheimer's Disease**

*Chair:* Anya Topiwala (Oxford, United Kingdom)

**Immuno-therapies for Alzheimer's disease work best in the earliest stages: prospects for primary and secondary prevention**

16:35 - 17:05

*Speaker:* Colin Masters (Australia)

**Pharmacological Properties of Brexpiprazole for the Treatment of Agitation in Alzheimer's Disease**

17:05 - 17:35

*Speaker:* Tetsuro Kikuchi (Japan)

*Spotlight Session*

16:35 - 17:35

S3

**Spotlight Session 6:**

**Between Passion and Pressure: Early Career Researchers Round Table**

*Chair:* Gabriella Gobbi (Montreal, Canada)

**Early Career Researchers Round Table**

16:35 - 17:35

*Speaker:* Gabriella Gobbi (Montreal, Canada)

*Speaker:* Lucie Bartova (Vienna, Austria)

*Speaker:* Diego A. Pizzagalli (Belmont, United States)

*Speaker:* Maria Teresa Ferretti (Klosterneuburg, Austria)

*Speaker:* Pornjira Pariwatcharakul (Bangkok, Thailand)

*Data Blitz Session*

16:35 - 17:35

M1

**Data Blitz 6: Psychosis characterization**

*Chair:* Kiyoyuki Kitaichi (Gifu, Japan)

**Shorter Telomere Length in Schizophrenia Patients Compared to Healthy Controls, Independent of Treatment, Psychotic Status, and Metabolic Factors**

16:35 - 16:41

*Speaker:* Pin-Wen Lai (Taipei, Taiwan)

**Haematological and inflammatory markers associated with non-remission and treatment resistance in schizophrenia**

16:41 - 16:47

*Speaker:* Yanhui Li (Singapore, Singapore)

**Feature selection and algorithm optimization for Brain age**

16:47 - 16:53

### **prediction in schizophrenia patients**

*Speaker:* Yen-Wei Chu (Taichung City, Taiwan)

#### **Revealing novel biomarkers and therapeutic targets Gene in schizophrenia a bioinformatic study through protein-protein interaction network analysis**

16:53 - 16:59

*Speaker:* Adicitra Auriel Bestari (Surabaya, Indonesia)

#### **Psychiatric comorbidity in patients with tinnitus or auditory hallucination and sleep evaluation, sound therapy and Shared Decision Making (SDM)**

16:59 - 17:05

*Speaker:* Kensuke Kiyomizu (Nobeoka, Miyazaki, Japan)

#### **To explore the effect of psychophysiological markers for stress regulation in patients with schizophrenia: an implication of cardiovascular risk**

17:05 - 17:11

*Speaker:* Yu-Wei Lin (Taichung, Taiwan)

#### **Clinical features and neural substrates underlying humor processing in patients with first episode schizophrenia**

17:11 - 17:17

*Speaker:* Bingjie Huang (Beijing, China)

#### **Prebiotics rescue gut microbiome dysregulation and enhance cognitive and gastrointestinal function in a mouse model of schizophrenia**

17:17 - 17:23

*Speaker:* Anthony J. Hannan (Parkville, Australia)

#### **Elevated levels of AKT-interacting protein in the frontal pole reveals molecular pathology specific to a subtype of people with schizophrenia**

17:23 - 17:29

*Speaker:* Megan Snelleks (Melbourne, Australia)

#### **Role of cognitive function in functional outcome in psychotic and affective inpatients**

17:29 - 17:35

*Speaker:* Gabriele Sachs (Vienna, Austria)

### *Posters*

16:35 - 17:35

M2

### **Outstanding Poster Presentation Session**

*Chair:* Rachel Hill (Clayton, Australia)

**Outstanding Poster Presentation Session: During the first days of the congress there will be a voting for posters available via the congress app. The 6 presenters with the most votes will have the opportunity to present their work in a 10 min talk during the "Outstanding Poster Presentation Session". We encourage all participants to support their peers by voting.**

16:35 - 17:35

### *Spotlight Session*

17:40 - 18:40

PL

### **Spotlight Session 9: Recent Advances in ADHD**

*Chair:* Yu-Ming Chen (Taipei, Taiwan)

#### **Recent Advances in ADHD**

17:40 - 18:10

*Speaker:* Susan Shur-Fen Gau (Taipei, Taiwan)

#### **Recent Advances in ADHD 2**

18:10 - 18:40

*Speaker:* David Coghill (Australia)



*Featured Communication*

17:40 - 18:40

S1

**Featured Communication 6: Steroids/Depression**

*Chair:* Hideki Miwa (Tokyo, Japan)

**Involvement of the gut-brain axis in food addiction**

17:40 - 17:55

*Speaker:* Rafael Maldonado (Barcelona, Spain)

**Increased sensitivity of central serotonergic neurons to corticosteroids following maternal immune activation: significance for mood disorders**

17:55 - 18:10

*Speaker:* Eliyahu Dremencov (Bratislava, Slovakia)

**Antidepressants interact with the components of sex steroid receptors**

18:10 - 18:25

*Speaker:* Shokouh Arjmand (Aarhus, Denmark)

**Differential Gene expression involving the epidermal growth factor (EGF) and immune system pathways in dorsolateral prefrontal (BA46) and orbitofrontal (BA11) cortical regions in mood disorders**

18:25 - 18:40

*Speaker:* Tharini Ketharanathan (Parkville, Australia)

*Data Blitz Session*

17:40 - 18:40

S2

**Data Blitz 7: Schizophrenia-related**

*Chair:* Yukiori Goto (Kyoto, Japan)

**Organizing the disorganization: an artificial intelligence-based decision supporting system for the detection of disorganization symptoms in schizophrenia and non-affected participants**

17:40 - 17:46

*Speaker:* Felice Iasevoli (Naples, Italy)

**Differences in Changes of Peptide Antigen-Related Antibody Levels Between Remission and Non-Remission Groups After One Year of Antipsychotic Treatment in Drug-Naïve First-Episode Schizophrenia Patients**

17:46 - 17:52

*Speaker:* Yue Zheng (Beijing, China)

**The association between brown adipose tissue (BAT)-brain axis activity and the risk of metabolic adversities in patients with schizophrenia treated with antipsychotic drugs (APDs)**

17:52 - 17:58

*Speaker:* Po-Yu Chen (Taipei, Taiwan)

**Oxytocin as a potential biomarker for metabolic syndrome in schizophrenia**

17:58 - 18:04

*Speaker:* Kah Kheng Goh (Taipei City, Taiwan)

**Effects of GLT-1 modulator, MC-100093, on neuroinflammatory factor in mesocorticolimbic brain regions of female P rats exposed chronically to ethanol**

18:04 - 18:10

*Speaker:* Youssef Sari (Toledo, United States)

**Neurophysiological insights into omission mismatch negativity: Evidence from macro calcium imaging in rat auditory cortex**

18:10 - 18:16

*Speaker:* Hiroyuki Nawa (Wakayama, Japan)

**The association between obstructive sleep apnea and psychiatric disorders: a population-based risk analysis**

18:16 - 18:22

*Speaker:* Chuan-Yi Kao (Taichung, Taiwan)

**Mice carrying the Arx<sup>R264Q</sup> mutation show sex-specific disruptions to parvalbumin and somatostatin interneuron densities**

18:22 - 18:28

*Speaker:* Victoria Edwards-Poulton (Clayton, Australia)

**Discussion, Q&A**

18:28 - 18:40

*Session*

17:40 - 18:40

S3

**CINP General Assembly: CINP Members only**

*Selected Colloquium*

17:40 - 18:40

M1

**Selected Colloquium 1: Effects of Early Life Adversity on the Structure of Common Mental Disorders: Reimagining the Diathesis-Stress Model**

*Chair:* Kim Felmingham (Melbourne, Australia)

**Connecting the transdiagnostic internalizing spectrum with epigenetic aging: a HiTOP approach**

17:40 - 18:00

*Speaker:* Robert Krueger (Minneapolis, United States)

**Measuring the accumulation of psychosocial stressors**

18:00 - 18:20

*Speaker:* Frank Mann (Stony Brook, United States)

**Reimagining the diathesis-stress model: transdiagnostic factors to precision psychiatry**

18:20 - 18:40

*Speaker:* Marco Leyton (Montreal, Canada)

*Selected Colloquium*

17:40 - 18:40

M2

**Selected Colloquium 7: Re-Evaluating 'Older' Drugs for the Treatment of Mood Disorders; a Focus on MAOI's, Lithium and Psychedelics**

*Chair:* Allan Young (London, United Kingdom)

**Psychedelics: current state and future prospects**

17:40 - 18:00

*Speaker:* Allan Young (London, United Kingdom)

**MAOIs: efficacy, tolerability and acceptability of MAOI's for the treatment of mood disorders**

18:00 - 18:20

*Speaker:* Paul Stokes (London, United Kingdom)

**Lithium: from Cade to the modern day**

18:20 - 18:40

*Speaker:* Janusz Rybakowski (Poznan, Poland)

*Networking*

18:40 - 20:00

SR

**CINP Members' Reception**

**Wednesday, 18. June 2025***Plenary*

09:10 - 10:10

PL

**Plenary 5: Keynote Lecture Patrick McGorry***Chair:* Kim Q. Do (Lausanne, Switzerland)*Chair:* Tian-Mei Si (Beijing, China)**The Global Youth Mental Health Crisis: Megatrends and Solutions**

09:10 - 10:10

*Speaker:* Patrick McGorry (Parkville, Australia)*Networking*

09:30 - 16:45

SR

**OPEN: Exhibition & CINP Members' Lounge***Break*

10:10 - 10:50

SR

**Morning Coffee Break***Symposium*

10:50 - 12:05

PL

**Symposium 13: Modulating the brain with light, sound and electric fields - the future of non-invasive brain stimulation in psychiatry?***Chair:* Lucie Bartova (Vienna, Austria)*Chair:* Georg Kranz (Hogn Kong, Hong Kong)**Transcranial magnetic stimulation in less common indications - focused on schizophrenia and borderline personality disorder**

10:50 - 11:15

*Speaker:* Libor Ustohal (Brno, Czech Republic)**Research on Transcranial Pulse Stimulation (TPS) in Major Depressive Disorder (MDD)**

11:15 - 11:40

*Speaker:* Georg Kranz (Hogn Kong, Hong Kong)**The use of intermittent light at 60Hz for brain entrainment and its effect on neuroplasticity in mice and modulation of EEG patterns in healthy humans**

11:40 - 12:05

*Speaker:* Maria Teresa Ferretti (Klosterneuburg, Austria)*Symposium*

10:50 - 12:05

S1

**Symposium 14: Genetic Insights into Individual Variability in the Effects of Addictive Substances***Chair:* Kazutaka Ikeda (Tokyo, Japan)**Genetic insights into cannabis use and use disorder.**

10:50 - 11:15

*Speaker:* Joel Gelernter (West Haven, United States)**The role of alcohol in dementia**

11:15 - 11:40

*Speaker:* Anya Topiwala (Oxford, United Kingdom)**Genetic polymorphisms associated with opioid sensitivity in patients undergoing palliative care and general anaesthesia**

11:40 - 12:05

*Speaker:* Daisuke Nishizawa (Tokyo, Japan)*Symposium*

10:50 - 12:05

S2

**Symposium 15: Neural Circuits of Dorsal Striatum and Amygdala in Addictive Behaviors***Chair:* Doo-Sup Choi (Rochester, United States)

<b>Indirect medium spiny neurons in the dorsolateral striatum projecting to the external globus pallidus regulate compulsive alcohol-seeking behaviors</b>	10:50 - 11:15
<i>Speaker:</i> Doo-Sup Choi (Rochester, United States)	
<b>The circuit basis of cocaine-induced orofacial stereotypies</b>	11:15 - 11:40
<i>Speaker:</i> Ami Citri (Jerusalem, Israel)	
<b>Dopaminergic control of compulsive eating</b>	11:40 - 12:05
<i>Speaker:</i> Ja-Hyun Baik (Seoul, Korea, Republic of)	
<i>Data Blitz Session</i> 10:50 - 12:05	S3
<b>Data Blitz 8: Schizophrenia treatment</b>	
<i>Chair:</i> Shyh-Yuh Wei (Tainan, Taiwan)	
<b>Successful Antipsychotic Dose Tapering Leading to Better Cognition in Patients with Remitted Psychosis: A 2-year Prospective Randomized-Controlled Trial</b>	10:50 - 10:56
<i>Speaker:</i> Chun-I Liu (Taipei, Taiwan)	
<b>Abnormalities of Subcortical Brain Volume throughout the Psychosis Course</b>	10:56 - 11:02
<i>Speaker:</i> Yi-An Liao (Taipei, Taiwan)	
<b>Clinical Practice Recommendations for Switching to Longer-Interval Injectable Antipsychotics in Schizophrenia Patients: A Modified Delphi Study in China</b>	11:02 - 11:08
<i>Speaker:</i> Wanyi Zhang (Beijing, China)	
<b>Design of a phase 3, potentially pivotal, international, randomized, double-blind, placebo-controlled trial with evenamide, a glutamate modulator, add-on to SGA in patients with treatment-resistant schizophrenia</b>	11:08 - 11:14
<i>Speaker:</i> Ravi Anand (St Moritz, Switzerland)	
<b>Effects of Semaglutide on Body Weight in Clozapine-Treated Individuals with Schizophrenia and Obesity: A Randomized Controlled Trial</b>	11:14 - 11:20
<i>Speaker:</i> Dan Siskind (Brisbane, Australia)	
<b>Novel augmentation strategies for clozapine resistant schizophrenia: the role of adaptive platform trials</b>	11:20 - 11:26
<i>Speaker:</i> Dan Siskind (Brisbane, Australia)	
<b>The benefits of clozapine beyond its antipsychotic properties in treatment-resistant schizophrenia</b>	11:26 - 11:32
<i>Speaker:</i> Kannan Subramaniam (Auckland, New Zealand)	
<b>Impacts of Taiwan's National Health Insurance Dedicated Budget Policy on Long-Acting Injectable Usage: An Interrupted Time-Series Analysis</b>	11:32 - 11:38
<i>Speaker:</i> Grace Hui-Min Wu (Taipei, Taiwan)	
<b>Exploring safe tapering of antipsychotics in patients with remitted psychosis: employing animal model and coadministration of N-Acetylcysteine study in bench and bedside</b>	11:38 - 11:44
<i>Speaker:</i> Chen-Chung Liu (Taipei, Taiwan)	
<b>Discussion, Q&amp;A</b>	11:44 - 12:05

*Data Blitz Session*

10:50 - 12:05

M1

**CINP invited Biological Psychiatry Australia Data Blitz 1: Focus on Development, Cognition, Stress, Depression, and Fear***Chair:* Tertia Purves-Tyson (Sydney, Australia)

**Adversity-related changes to the spatial localisation of hippocampal cortisol receptors in psychiatric disorders** 10:50 - 10:56

*Speaker:* Amber Curry (Sydney, Australia)

**Endocannabinoids and intrusive memories: Evidence for a role of anandamide from two experimental human studies** 10:56 - 11:02

*Speaker:* Luke Ney (Brisbane, Australia)

**Prebiotics improve motor function, cognition and gut health in a preclinical model of Huntington's disease** 11:02 - 11:08

*Speaker:* Millicent Ekwudo (Melbourne, Australia)

**Linking Oestradiol (E2) Timing and Tempo, Brain Development, and Mental Health in Adolescent Females** 11:08 - 11:14

*Speaker:* Muskan Khetan (Melbourne, Australia)

**Temporal immune effects of oral ketamine on PTSD: transcriptomic evidence of short-term inflammation suppression and long-term immune remodelling** 11:14 - 11:20

*Speaker:* Nathan Wellington (Birtinya, Australia)

**Paternal immune activation via the viral mimic poly I:C leads to epigenetic changes in sperm and results in behavioural, brain and physiological changes in offspring** 11:20 - 11:26

*Speaker:* Nicholas Van de Garde (Melbourne, Australia)

**The impact of paternal cytokine administration on sperm small RNAs and offspring physiology and behaviour in mice** 11:26 - 11:32

*Speaker:* Pamudika Kiridena (Melbourne, Australia)

**Differential striatal gene expression profiles underlying the propensity for depression-like behaviour in a mouse model of vertical sleeve gastrectomy** 11:32 - 11:38

*Speaker:* Renee Papaluca (Melbourne, Australia)

**Baricitinib Reverses Depressive and Cognitive Deficits in a Rodent Model of Treatment-Resistant Depression** 11:38 - 11:44

*Speaker:* Roger Bitencourt Varela (Brisbane, Australia)

**Modelling cognitive and psychiatric behavioural traits in a mouse model of Neurofibromatosis type I** 11:44 - 11:50

*Speaker:* Sonali N. Reisinger (Melbourne, Australia)

**Whole brain activity mapping of the effects of a novel small molecule on chronic social isolation induced aggression in mice** 11:50 - 11:56

*Speaker:* Terry Salthouse (Sydney, Australia)

**The Effects of Maternal Immune Activation on the Phospho-Proteome of the Developing Adolescent Mouse Hippocampus** 11:56 - 12:02

*Speaker:* Ulysse Thivisol (Melbourne, Australia)

**Q&A, Discussion** 12:02 - 12:05

*Spotlight Session*

12:15 - 13:15

PL

**Spotlight Session 10: Treatment Resistant Depression (TRD): basic science and clinical reality***Chair:* Pierre Blier (Ottawa, Canada)

**Clinical reality of Treatment Resistant Depression (TRD)** 12:15 - 12:45

Speaker: Siegfried Kasper (Vienna, Austria)

### Basic Science of Treatment Resistant Depression (TRD)

12:45 - 13:15

Speaker: Dan Rujescu (Wien, Austria)

Data Blitz Session

12:15 - 13:15

S1

### Data Blitz 9: OCD/behavioral

Chair: Shih-Ku Lin (Taipei, Taiwan)

#### Neural mechanisms of Brain-lymph nodes axis in stress-induced anxiety disorders

12:15 - 12:21

Speaker: Dong Dong Shi (Shanghai, China)

#### Pathological Networking of Gray Matter Dendritic Density With Classic Brain Morphometries in OCD

12:21 - 12:27

Speaker: Qing Fan (Shanghai, China)

#### Characterising the neuropeptide landscape of the postmortem human orbitofrontal cortex in health, following severe childhood adversity and in psychopathology

12:27 - 12:33

Speaker: Katrina Z. Edmond (Sydney, Australia)

#### Identifying specific EEG markers of Internet Gaming Disorder and the corresponding tDCS intervention: a randomized controlled double-blind study

12:33 - 12:39

Speaker: Yixuan Song (Beijing, China)

#### Changes in brain biochemical metabolites of cognitive flexibility impairment in non-medicated obsessive-compulsive disorder patients

12:39 - 12:45

Speaker: Yanbin Jia (Guangzhou, China)

#### Common and distinct neural substrates of cue craving response between substance and behavioral addiction: a neuroimaging meta-analysis

12:45 - 12:51

Speaker: Qihong Zheng (Beijing, China)

#### Role of orexin in reward-based decision-making strategies

12:51 - 12:57

Speaker: Hiroyuki Mizoguchi (Nagoya, Japan)

#### Correlation between trace elements and cognitive impairment in patients with first diagnosis of obsessive-compulsive disorder

12:57 - 13:03

Speaker: Yiliang Zhang (Guangzhou, China)

#### A Novel, Non-Hallucinogenic Psychedelic for the Treatment of OCD and Tic Disorder

13:03 - 13:09

Speaker: Bernard Lerer (Jerusalem, Israel)

#### Discussion, Q&A

13:09 - 13:15

Data Blitz Session

12:15 - 13:15

S2

### Data Blitz 10: Basic research-variable

Chair: Lalit K. Srivastava (Montreal, Canada)

#### Analysis of the effect of oxytocin analogues on a mouse contextual fear-conditioning behavior

12:15 - 12:21

Speaker: Kento Igarashi (Kagoshima City, Japan)

#### Cerebellar $\alpha 6$ GABA<sub>A</sub> receptor as a potential therapeutic target for relieving core symptoms of autism: a preclinical study in prenatal valproic acid-exposure rats

12:21 - 12:27

Speaker: Lih-Chu Chiou (Taipei, Taiwan)

<b>Agonism Heterogeneity: anti-amnesic SIGMAR1 agonists PRE-084 and (+)pentazocine differentially translocate SIGMAR1 to substructures of endoplasmic reticulum in Neuro2a cells</b>	12:27 - 12:33
<i>Speaker:</i> Yuko Yasui (Baltimore, United States)	
<b>High-speed treadmill running in young and old mice recorded with marker-based 3D motion capture</b>	12:33 - 12:39
<i>Speaker:</i> Bogna Ignatowska-Jankowska (Onna, Japan)	
<b>Paternal chronic bacterial-like infection induces intergenerational changes in offspring anxiety and cognition</b>	12:39 - 12:45
<i>Speaker:</i> Da Lu (Parkville, Australia)	
<b>Effects of Teneurin-4 knockdown in the prefrontal cortex on depressive behaviors in mice</b>	12:45 - 12:51
<i>Speaker:</i> Yusuke Yano (Toyama, Japan)	
<b>M4 muscarinic receptor activation in the central amygdala reduces stress-induced alcohol seeking in alcohol preferring rats</b>	12:51 - 12:57
<i>Speaker:</i> Roberta G Anversa (Melbourne, Australia)	
<b>Uncovering the role of GlyT2+ periaqueductal grey neurons in pain and pain-related behaviours</b>	12:57 - 12:57
<i>Speaker:</i> Caitlin Fenech (St Leonards, Australia)	
<b>Discussion, Q&amp;A</b>	12:57 - 13:15
<i>Featured Communication</i> 12:15 - 13:15	S3
<b>Featured Communication 7: Psychedelics related</b>	
<i>Chair:</i> Danilo De Gregorio (Milan, Italy)	
<b>Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration</b>	12:15 - 12:30
<i>Speaker:</i> Bernard Lerer (Jerusalem, Israel)	
<b>A long noncoding eRNA forms R-loops to shape emotional experience-induced behavioral adaptation</b>	12:30 - 12:45
<i>Speaker:</i> Makoto Taniguchi (Charleston, United States)	
<b>Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring</b>	12:45 - 13:00
<i>Speaker:</i> Cassandra Hatzipantelis (Davis, United States)	
<b>Discussion, Q&amp;A</b>	13:00 - 13:15
<i>Selected Colloquium</i> 12:15 - 13:15	M1
<b>Selected Colloquium 10: Promises and Pitfalls of Clinical Trial Design: How can we better evaluate novel target antipsychotics?</b>	
<i>Chair:</i> Anthony Grace (Pittsburgh, United States)	
<b>N-Acetyl-Cysteine (NAC) Intervention and Mitochondrial Mechanisms in- Early Psychosis Patients</b>	12:15 - 12:35
<i>Speaker:</i> Kim Q. Do (Lausanne, Switzerland)	
<b>Examining novel therapies within a clinical staging framework</b>	12:35 - 12:55
<i>Speaker:</i> Patrick McGorry (Parkville, Australia)	
<b>Preclinical studies of standard and novel target antipsychotic drugs in animal models of schizophrenia: Why clinical trials may have failed to recapitulate preclinical findings</b>	12:55 - 13:15
<i>Speaker:</i> Anthony Grace (Pittsburgh, United States)	

*Meet the Experts / Campfire Session*

12:15 - 13:15

M2

**Meet the Expert 4: Schizophrenia (LIMITED SEATS)**

*Chair:* Jimmy Lee (Singapore, Singapore)

**Schizophrenia: Case Discussions**

12:15 - 13:15

*Speaker:* Dan Siskind (Brisbane, Australia)

*Speaker:* Andrew Thompson (Australia)

*Break*

13:15 - 14:40

SR

**Lunch Break**

*Sponsored Symposium*

13:25 - 14:25

S1

**Sponsored Lunch Symposium**

*Symposium*

14:40 - 15:55

PL

**Symposium 16: Muscarinic M1 and M4 receptors: Drug development, a treatment for schizophrenia and a potential treatment for addiction**

*Chair:* Suresh Sundram (Clayton, Australia)

**The development of drugs to activate the muscarinic M1 and M4 receptors to treat disorders of the human CNS**

14:40 - 15:05

*Speaker:* Carrie K. Jones (Nashville, United States)

**Muscarinic receptors and the molecular pathology of schizophrenia**

15:05 - 15:30

*Speaker:* Brian Dean (Parkville, Australia)

**Muscarinic M1 and M4 receptor stimulation reverse effects of cocaine across several assays**

15:30 - 15:55

*Speaker:* Morgan Thomsen (Copenhagen, Denmark)

*Symposium*

14:40 - 15:55

S1

**Symposium 17: Connecting the Dots in Opioid Addiction: Brain Circuits, Stress, and Clinical Trials**

*Chair:* Kazutaka Ikeda (Tokyo, Japan)

**Targeting the ventral pallidum to treat opioid use disorder**

14:40 - 15:05

*Speaker:* Meaghan Creed (St. Louis, United States)

**Understanding the impact of acute and chronic opioid exposure on endocannabinoid function and stress sensitivity in humans**

15:05 - 15:30

*Speaker:* Leah Mayo (Calgary, Canada)

**Alleviating opioid withdrawal: from rodents to human clinical trial**

15:30 - 15:55

*Speaker:* Tuan Trang (Calgary, Canada)

*Symposium*

14:40 - 15:55

S2

**Symposium 18: Neurodevelopmental Disorder Models and Mechanisms**

*Chair:* Noriko Osumi (Sendai, Japan)

**Deficiency of *Tbx1*, a gene encoded in 22q11.2 copy number variation, impairs social and cognitive behaviors by altering brain shape and neonatal stem cells**

14:40 - 15:05

*Speaker:* Noboru Hiroi (San Antonio, United States)

**The role of NPAP1 ancestral and modern variants on circadian rhythms and lipid metabolism in Prader-Willi syndrome**

15:05 - 15:30



Speaker: Valter Tucci (Genova, Italy)

**Brain development in Fragile X syndrome: sex difference and parental epigenetic effect in the mouse model**

15:30 - 15:55

Speaker: Takako Kikkawa (Sendai, Japan)

Data Blitz Session

14:40 - 15:55

S3

**Data Blitz 11: Clinical research-variable**

Chair: Malcolm Hopwood (Melbourne, Australia)

**Clinical psychological predictors in process of formation gender asymmetries**

14:40 - 14:46

Speaker: Aleksandr Kim (Bishkek, Kyrgyzstan)

**Trihexyphenidyl Reduces Flashbacks in Patients with Posttraumatic Stress Disorder (PTSD)**

14:46 - 14:52

Speaker: Sogou Katsumasa (Hiroshima City, Japan)

**Exploration of the mechanism of action of massage interventions in human subjects**

14:52 - 14:58

Speaker: Mark Rapaport (Salt Lake City, United States)

**Prescription pattern and medical expenses in executive psychiatric clinic - RSUD Dr. Chasbullah Abdulmajid (Type B government hospital) Bekasi City Indonesia - period March - November 2024**

14:58 - 15:04

Speaker: Chrisna Mayangsari (Bekasi, Indonesia)

**Psilocybin and ketanserin vs rTMS in treatment-resistant depression: enhancing tolerability by mitigating psychedelic effects**

15:04 - 15:10

Speaker: Giovanni Martinotti (Chieti, Italy)

**Mental Health Australia General Clinical Trial Network (MAGNET) - connecting knowledge for better mental health outcomes**

15:10 - 15:16

Speaker: Michael Berk (Geelong, Australia)

**L-methylfolate: from novel agent to mainstream psychiatric practice**

15:16 - 15:22

Speaker: Vivienne Mak (Melbourne, Australia)

**Collecting and evaluating animal models in mental health science and building an online resource for researchers: a Wellcome initiative**

15:22 - 15:28

Speaker: Rachel Hill (Clayton, Australia)

**Discussion, Q&A**

15:28 - 15:55

Data Blitz Session

14:40 - 15:55

M1

**CINP invited Biological Psychiatry Australia Data Blitz 2: Focus on Schizophrenia and Psychosis**

Chair: Ariel Dunn (Melbourne, Australia)

**Investigating cellular phenotypes and genotypes of a preclinical model relevant to schizophrenia using single-cell RNA sequencing**

14:40 - 14:45

Speaker: Angel Yonehara (Melbourne, Australia)

**Iron dyshomeostasis is linked to downregulated amyloid precursor protein in schizophrenia prefrontal cortex: a postmortem study**

14:45 - 14:50

Speaker: Carlos M Opazo (Melbourne, Australia)

**Cholinergic muscarinic type 4 receptor dominates Xanomeline's efficacy, with essential contribution from type 1 receptor**

14:50 - 14:55

Speaker: Christopher Choy (Melbourne, Australia)

<b>Sex-dependent and dynamic brain structural MRI changes in mice following influenza A virus maternal immune activation</b>	14:55 - 15:00
<i>Speaker:</i> Danli Peng (Melbourne, Australia)	
<b>Dissecting Epigenetic Heterogeneity in Schizophrenia</b>	15:00 - 15:05
<i>Speaker:</i> Dylan Kiltschewskij (Newcastle, Australia)	
<b>Schizophrenia-like endophenotypes in Amyloid Precursor Protein knock out mice</b>	15:05 - 15:10
<i>Speaker:</i> Jackson Choong (Melbourne, Australia)	
<b>Patient-derived microglia-containing organoids for investigating neuroanatomical phenotypes in schizophrenia</b>	15:10 - 15:15
<i>Speaker:</i> Jordan Clarke (Melbourne, Australia)	
<b>Relationship between electroencephalography-based mismatch negativity and antipsychotic treatment response in young people at clinical high risk for psychosis</b>	15:15 - 15:20
<i>Speaker:</i> Magdalene de Rozario (Melbourne, Australia)	
<b>Serum iron abnormalities in Treatment resistant Schizophrenia are not observed in Frontotemporal dementia</b>	15:20 - 15:25
<i>Speaker:</i> Naimisha Talluri (Melbourne, Australia)	
<b>Serum elements and oxidative stress indices are altered in treatment-resistant schizophrenia</b>	15:25 - 15:30
<i>Speaker:</i> Sandra Luza (Melbourne, Australia)	
<b>Maternal immune activation and estrogen receptor modulation induce sex-specific dopamine-related behavioural and molecular alterations in adult rat offspring</b>	15:30 - 15:35
<i>Speaker:</i> Sophie Debs (Sydney, Australia)	
<b>Are psychiatric diagnoses associated with a robust neuroanatomical phenotype? An assessment of the reproducibility of grey matter differences in mental illness</b>	15:35 - 15:40
<i>Speaker:</i> Trang Cao (Clayton, Australia)	
<b>Using large-scale genetic studies to find drug targets in schizophrenia: where are we at?</b>	15:40 - 15:45
<i>Speaker:</i> William Reay (Hobart, Australia)	
<b>Discussion, Q&amp;A</b>	15:45 - 15:55
<i>Break</i> 15:55 - 16:35	SR
<b>Afternoon Coffee Break</b>	
<i>Featured Communication</i> 16:35 - 17:35	PL
<b>Featured Communication 8: Cognition related</b>	
<i>Chair:</i> Noriko Osumi (Sendai, Japan)	
<b>Selective potentiation of <math>\alpha 5</math>-GABAA receptors contributes to reduction of cognitive burden and neuronal loss in aging mice - **Rafaelsen Young Investigators Award 2025**</b>	16:35 - 16:50
<i>Speaker:</i> Thomas Prevot (Toronto, Canada)	
<b>Mechanisms and pharmacological therapy of intergenerational neurocognitive deficiencies induced by exposure to the general anesthetic sevoflurane</b>	16:50 - 17:05
<i>Speaker:</i> Anatoly Martynyuk (Gainesville, United States)	
<b>Sensors in-home for elder wellbeing (SINEW): digital phenotyping</b>	17:05 - 17:20

**and artificial intelligence for early detection of dementia***Speaker:* Iris Rawtaer (Singapore, Singapore)**The effectiveness of vagus nerve stimulation in the treatment of alzheimer's and parkinson's disease: a systematic review**

17:20 - 17:35

*Speaker:* Ruihua Hou (Southampton, United Kingdom)*Featured Communication*

16:35 - 17:35

S1

**Featured Communication 9: Variable***Chair:* Lucie Bartova (Vienna, Austria)**Microglia integrates multiple stress signals via distinct molecular pathways for behavioral dysfunctions**

16:35 - 16:50

*Speaker:* Tomoyuki Furuyashiki (Kobe, Japan)**Predicting intermittent TBS treatment response in patients with major depressive disorder using concurrent TBS/fNIRS and machine learning**

16:50 - 17:05

*Speaker:* Rebecca Kan (Hong Kong, China)**A Study on Co-Administration of Metformin along with Olanzapine on Changes in Body Weight, Waist Circumference, Fasting Blood Sugar and Lipid Profile in schizophrenia**

17:05 - 17:20

*Speaker:* Gautam Saha (Kolkata, India)**Evenamide, a glutamate modulator, provided statistically significant benefits when added to SGA in patients with schizophrenia: phase 2/3, international, randomized, double-blind, placebo-controlled study results**

17:20 - 17:35

*Speaker:* Ravi Anand (St Moritz, Switzerland)*Featured Communication*

16:35 - 17:35

S2

**Featured Communication 10: Schizophrenia/Variable***Chair:* Suresh Sundram (Clayton, Australia)**Converging human-specific evidence implicates astrocytic glutamate regulation in stress-related psychiatric disorders**

16:35 - 16:50

*Speaker:* Natalie Matosin (Sydney, Australia)**Epitranscriptomic regulation of striatal function: a new neurobiology of schizophrenia?**

16:50 - 17:05

*Speaker:* Xiaoying Cui (Brisbane, Australia)**Longitudinal cortical thickness changes in first episode psychosis: a triple-blind randomised placebo-controlled MRI study**

17:05 - 17:20

*Speaker:* Sidhant Chopra (Melbourne, Australia)**Microglia/Macrophage transcripts are increased in neuroinflammatory schizophrenia and bipolar disorder midbrains**

17:20 - 17:35

*Speaker:* Gerardo Mendez-Victoriano (Sydney, Australia)*Featured Communication*

16:35 - 17:35

S3

**Featured Communication 11: Depression/Variable***Chair:* Nasser Haddjeri (Bron, France)**Linking prenatal inflammation to synaptic dysfunction in psychiatric disorders**

16:35 - 16:50

*Speaker:* Jose Agustin Cota Coronado (Melbourne, Australia)**Efficacy of lumateperone 42 mg in the treatment of major**

16:50 - 17:05

**depressive disorder: a pooled analysis of phase 3 randomized controlled trials**

*Speaker:* Suresh Durgam (Bedminster, United States)

**Identification of blood biomarkers of psilocybin-assisted therapy treatment response for generalised anxiety disorder**

17:05 - 17:20

*Speaker:* Andrew Gibbons (Clayton, Australia)

**Long-term adjunctive lumateperone treatment in major depressive disorder: results from a six-month open-label extension study**

17:20 - 17:35

*Speaker:* Willie Earley (Bedminster, United States)

*Data Blitz Session*

16:35 - 17:35

M1

**CINP invited Biological Psychiatry Australia Data Blitz 3: Focus on Addition and Eating Disorders**

*Chair:* Leigh Walker (Melbourne, Australia)

**Exploring the potential of gut taste receptors for the treatment of disordered eating behaviour**

16:35 - 16:41

*Speaker:* Caiwei lin (Melbourne, Australia)

**Uncovering multiday patterns in regulatory control: A personalized framework for capturing longer-term patterns in self-regulation**

16:41 - 16:47

*Speaker:* Jodie Naim-Feil (Melbourne, Australia)

**Estrous cycle-dependent effects of a tropomyosin receptor kinase B agonist on fear extinction in female adolescent rats**

16:47 - 16:53

*Speaker:* Kathryn Baker (Melbourne, Australia)

**Insights into the post-acute effects of psilocybin on reward-driven dopaminergic responses during probabilistic reversal learning in female rats**

16:53 - 16:59

*Speaker:* Kyna Conn (Clayton, Australia)

**Assessing the utility of zuranolone to modify alcohol-related behaviours**

16:59 - 17:05

*Speaker:* Lauren Ursich (Melbourne, Australia)

**Investigating the role of orexin in stress-induced binge eating in female mice**

17:05 - 17:11

*Speaker:* Mia Jessica O'Shea (Melbourne, Australia)

**Investigating the potential of psilocybin for compulsive eating in a rat model of binge eating**

17:11 - 17:17

*Speaker:* Nicolo Fabila (Melbourne, Australia)

**Feasibility and preliminary efficacy of N-Acetylcysteine for loss of control eating: an open label study**

17:17 - 17:23

*Speaker:* Robyn Brown (Parkville, Australia)

**Ghrelin receptor signalling in the Edinger-Westphal nucleus regulates binge drinking in a sex-specific manner**

17:23 - 17:29

*Speaker:* Xavier Maddern (Melbourne, Australia)

**Discussion, Q&A**

17:29 - 17:35

*Plenary*

17:40 - 18:25

PL

**Closing Ceremony**